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ABSTRACT 
 
 In airways, secreted mucins absorb large volumes of water to form viscoelastic 
mucus, which is then propelled proximally by ciliary beating and swallowed. Mucins are 
secreted both at a low baseline rate and a high agonist-stimulated rate; baseline secretion 
is primarily responsible for clearance of inhaled particles and pathogens, while 
stimulated secretion can induce airway obstruction protectively to trap helminths 
traversing the lungs or pathologically in asthma. 
Exocytosis requires a SNARE complex acting in concert with a Munc18 
scaffolding protein. We previously found that Munc18b has the major scaffolding role in 
stimulated mucin secretion using heterozygous knockout mice. Here, we sought to 
identify the Munc18 protein mediating baseline secretion, and to test the hypothesis that 
selective impairment of stimulated secretion can protect against airway mucus 
obstruction.  
Using conditional airway epithelial deletant mice, we found that Munc18a has 
the major role in baseline mucin secretion, Munc18b has the major role in stimulated 
mucin secretion, and Munc18c does not function in mucin secretion. In an allergic 
asthma model, Munc18b deletion reduced airway mucus occlusion and airflow 
resistance. In a cystic fibrosis model, Munc18b deletion reduced airway mucus occlusion 
and emphysema. Munc18b deficiency in the airway epithelium did not result in any 
abnormalities of lung structure, particle clearance, inflammation, or bacterial infection. 
Our results show that regulated secretion in a polarized epithelial cell may involve more 
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than one exocytic machine at the apical plasma membrane, and that the protective roles 
of mucin secretion can be preserved while therapeutically targeting its pathologic roles. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Mucin biology: an overview 
1.1.1 Mucin structural organization 
1.1.1.1 Secretory cells 
 The conducting airways of the lung are lined by a pseudostratified columnar 
epithelium that consists of two principal cell types — ciliated and secretory (Fig. 1.1) 
(1). Both cell types are present in similar numbers, intermixed throughout the 
epithelium.  
Secretory cells are responsible for producing and secreting gel-forming mucins 
into the airway lumen (Fig. 1.1). They can be further divided into club, goblet, mucous 
and serous cells based on their appearance under a microscope (2). Club and goblet cells 
are found in the airway surface epithelium while mucous and serous cells are found in 
submucosal glands. Club, goblet and mucous cells produce and secrete mucins while 
serous cells do not secrete mucins, but liquid and antimicrobial peptides. Goblet cells 
show a typical accumulation of intracellular mucin. These intracellular mucins granules 
can be detected by Periodic Acid/Schiff (PAS) staining, or by its fluorescent version 
(PAFS) as we will see later in this document. In the PAS or PAFS reaction, mucins are 
stained when the sugar residues present on the mucin core undergo a periodate oxidation 
of their hydroxyl groups. The resulting aldehyde groups then react with Schiff’s reagent 
to produce the purple color for PAS or the red fluorescence for PAFS.  
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Figure 1.1. Composition of the surface epithelium. Ciliated cells express 
approximately 200 cilia. Secretory cells show small, black apical granules containing 
proteins and large yellow granules containing mucins. The mucus layer moves over an 
immobile periciliary layer that is approximately 7 µm deep. Reprinted from (2). 
 
 
 
Ciliated cells possess approximately 300 ~7 µm long cilia across the apical cell 
surface that sweep the mucus layer out of the lungs by beating.  Ciliated cells originate 
from secretory cells and are considered terminally differentiated, as they do not further 
differentiate or proliferate after epithelial injury (3). 
1.1.1.2 Mucus composition 
 Mucus plays an important role in providing an essential barrier that constitutes 
the first line of defense from inhaled particles and pathogens. These toxicants are 
trapped in the mucus layer and swept out of the lungs by ciliary action into the pharynx 
where they are swallowed, constituting a process called mucociliary clearance (2). 
Clearance of recruited leukocytes, dead cells, and endogenous debris is also carried out 
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by mucociliary clearance. Mucus has physical characteristics on the border between a 
viscous fluid and a soft elastic solid, which is essential to allow ciliary beating and 
proper clearance out of the lungs. These characteristics are conferred by a dilute network 
of polymerized mucins in water. In healthy airway mucus, water accounts for ~98% of 
the mass, while salts, mucins and non-mucin macromolecules for the other ~2%. The 
dense glycosylation of secreted mucins gives them the ability to interact with such large 
volumes of water, which can reach more than 100-fold their mass of water.  
 The mucus layer sits on top of a dense periciliary layer (Fig. 1.1). Its dense 
property is a result of the presence of membrane-tethered glyconjugates, including 
glycosaminoglycans and membrane-anchored mucins that prevent the penetration of the 
mucus layer but also provide hydration to the periciliary layer through bound water (4). 
The periciliary layer is 7 µm deep and its depth is controlled by the concentrations of 
ATP, UTP and adenosine. Ciliated cells sense mechanical stress during ventilation and 
secrete ATP, and secretory cells release uridine conjugates. In response to extracellular 
concentrations of ATP and uridine conjugates, P2Y2 receptors are activated, which 
stimulates chloride release and inhibits sodium absorption, resulting in water moving 
into the airway lumen (5, 6). The cystic fibrosis transmembrane conductance regulator 
(CFTR) also plays a crucial role in fluid homeostasis. Elevation of cAMP leads to 
protein kinase A mediated phosphorylation of CFTR, opening the channel and allowing 
for efflux of chloride and bicarbonate (7).  
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1.1.1.3 Mucin glycoproteins 
 Mucins are extremely large, heavily glycosylated proteins that are the major 
macromolecular components of mucus. Mucins are encoded by the MUC (MUC refers to 
human genes and Muc to murine) genes. There are 21 MUC genes identified, and their 
products are mainly classified into two groups, secreted mucins and membrane-
associated mucins. Secreted mucins are packaged and secreted into the airway lumen via 
secretory granules, whereas membrane-bound mucins are anchored into the plasma 
membrane via a transmembrane domain.  Of the 21 mucins, seven are highly expressed 
in the airway (8). Among those seven, two are gel-forming secreted polymeric mucins 
(MUC5B, MUC5AC), four are membrane-associated mucins (MUC1, MUC4, MUC16, 
MUC20), and one is a secreted, non-gel forming mucin (MUC7) (9).  
 MUC5B is produced in secretory cells of the surface epithelium and of 
submucosal glands, while MUC5AC is produced in proximal airways by goblet cells of 
the surface epithelium. MUC7 is expressed in submucosal glands. MUC4 is expressed 
on the cilia of ciliated cells. MUC1 is expressed on the cell surface and microvilli of 
both secretory and ciliated cells. While MUC1 is smaller than MUC4, it has a 
cytoplasmic tail that can generate a cascade of intracellular signaling that is active in 
pathogen defense. MUC16, which is the largest mucin, is present in both secretory and 
ciliated cells and possesses a transmembrane domain that is able to be cleaved to become 
part of the mobile mucus layer (4, 10). 
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1.1.1.4 Mucin structure 
 The length of mucin apoproteins ranges from 1000 to over 5000 amino acids (or 
300-500 kDa). Muc5b and Muc5ac monomers are around 500 nm long and they form 
homotypic polymers that reach at lengths up to hundreds of micrometers (11, 12). Both 
mucins contain glycosylated domains rich in proline, threonine, and serine residues (PTS 
domains), in addition to von Willebrand factor D (vWD)-like domains and cysteine-rich 
domains (CysD) (Fig. 1.2) (13). 
 
Figure 1.2. MUC5AC/MUC5B structural domains. MUC5AC and MUC5B 
apoproteins contain PTS domains (light blue ovals) interspersed with CysD (dark blue 
ovals), capped with vWD-like domains (black ovals). Reprinted from (14).  
 
 
 
 PTS domains are present in all mucins. They are centrally located in the mucin 
apoprotein, found in tandem repeats, and serve as sites for mucin glycosylation (more 
specifically, O-glycosylation, see below). Mucins consist of 50-90% carbohydrates — 
this property allows glycosylation modifications to increase the mass of mucins up to 5-
fold (13). PTS domains vary in length, from 7 amino acids in Muc19 to 375 in Muc3a, 
and frequency, from 10 to 500 repeats between different mucins (15). The specific 
sequences of PTS domains vary significantly among homologous mucin genes and 
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among different species, which provides unique characteristics to each mucin, such as 
different number of carbohydrate side chains or different crosslinking patterns (16).  
 Mucin polymerization is mediated by vWD-like domains. These cysteine rich 
domains are located at the N-terminus and C-terminus of secreted mucin proteins that 
allows for the creation of disulfide bonds and resulting dimerization. Muc5b and Muc5ac 
form homodimers in the endoplasmic reticulum (ER) via C-terminal-to-C-terminal 
disulfide bonds (Fig. 1.3). Homodimers are then polymerized in the Golgi via N-
terminal-to-N-terminal linkage, resulting in a linear conformation or in a tetrad-like 
structure (17).  
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Figure 1.3. Intracellular assembly of polymeric mucins. (1) In the endoplasmic 
reticulum, mucin protein undergoes intramolecular disulfide bond formation in their N- 
and C- termini as well as in their internal CysD domains. (2) Disulfide bonds form 
between C-terminal domains forming homodimers. (3) In the cis Golgi, GalNAc is 
added to the PTS domains. (4) Further glycosylation occurs as mucins travel through the 
Golgi. (5) Mucin dimers polymerize through intermolecular disulfide bonds, giving rise 
to linear or branched structures (left, old model), or linear or tetrad-like structures (right, 
new model). Adapted from (13, 14). 
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 CysD domains function as additional sites for mucin glycosylation and are 
located interspersed among PTS domains (18). The position of these domains may also 
confer flexibility, allowing mucin polymerization. A more specific type of glycosylation 
is attributed to the CysD domains, mannosylation. Muc5b has seven potential 
mannosylation sites and Muc5ac has nine. Mannosylation may have a role in 
intracellular trafficking, protein folding and protein localization. It is known that 
mannosylation is essential for the maturation of Muc5b and Muc5ac since mutations in 
the mannosylation sites arrest mucins in the ER and prevent their proper folding (19). 
1.1.1.5 Mucin glycosylation 
 Mucin O-glycosylation occurs in the Golgi and can be separated into three steps 
— initiation, elongations and termination. During initiation, N-acetylgalactosamine 
(GalNAc)-transferase transfers a single GalNAc to the hydroxyl side group of serines 
and threonines within the PTS domains (Fig. 1.4) (20). There are around 20 GalNAc-
transferases, and some are only able to function with unglycosylated proteins, while 
others need a glycosylated protein as substrate. Once the first GalNAc is placed, neutral 
sugars can be attached constitutively, making up the 4 “core” structures. Core 1 structure 
is formed by the addition of galactose (Gal) to the GalNAc-O-Ser/Thr. Core 2 structure 
is formed by the addition of N-acetylglucosamine (GlcNAc) to the core 1 structure. Core 
3 structure is formed by the addition of GlcNAc to the GalNAc-O-Ser/Thr, and core 4 
structure is formed by the branching of a core 3 structure and the addition of a second 
GlcNAc to the GalNAc-O-Ser/Thr. After core formation, elongation continues by 
sequential addition of Gals and GlcNAcs to form long strands in the case of cores 1 and 
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3, or bi-antennary structures in the case of cores 2 and 4 (21). These bi-antennary 
structures can further branch to become tri- or tetra-antennary. Glycans can also be 
modified by the addition of fucose, a common glycan in Muc5ac. For the termination 
step, these glycosylated structures end in Gal or GlcNAc, referred to as the uncapped 
glycoproteins, or they can be capped by sialic acid or sulfate. The resulting combination 
of glycans is highly variable; therefore, it is possible for the same mucin protein to have 
different glycosylation patterns even when expressed in the same tissue. For example, a 
study found over 100 different O-linked oligosaccharides structures in a single MUC2 
protein (22). Different glycosylation patterns provide different physical properties to 
each mucin. For example, sialic acid and sulfates confer negative charges to the strands, 
which makes glycosylated side chains repel each other and mucin glycoproteins more 
rigid. These properties end up affecting the viscosity of the mucus layer, as they can 
regulate the number of water molecules each mucin interacts with (14).  
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Figure 1.4. PTS domains showing the four core glycosylation structures. GalNAc 
(yellow squares) is attached to serine or threonine residues in all four core structures. 
This is followed by galactose (yellow circles) to form core 1, addition of both a 
galactose and a GlcNAc (blue squares) to form core 2, GlcNAc to form core 3, or 
addition of two GlcNAc to form core 4. These cores can be further elongated by the 
addition of extra sugars such as fucose (red triangles) to form long strands or bi-
antennary structures, or capped by SO4 (gray circles) or sialic acid (purple diamonds). 
Reprinted from (14). 
 
 
 
1.1.2 Mucin production and function 
1.1.2.1 Muc5b 
 Muc5b is the predominant polymeric mucin in airway mucus in healthy 
conditions. It is produced both by the surface epithelium and submucosal glands (2). By 
immunohistochemistry, Muc5b is visible throughout the surface epithelium from the 
trachea distally to (but not including) terminal bronchioles (23). With exposure to 
inflammatory stimuli, such as IL-1β, mucin production can go up several fold. The 
transcriptional mechanisms that regulate MUC5B/Muc5b expression are not yet well 
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understood. Some studies have shown that the transcription factor Nkx2.1 inhibits 
Muc5b gene expression (24), while other studies have shown that GATA6 may activate 
Muc5b expression (25).  
 Deletion of the major constitutively-expressed airway mucin, Muc5b, results in a 
severe defect in mucociliary clearance of particles and pathogens in mice, and in 50% 
mortality by 6 months of age (26). Partial reductions in Muc5b result in corresponding 
reductions in particle clearance and may be a factor in the increased susceptibility to 
lung infection with ageing (27). Protection against lung infection is likely to have driven 
selection of an allele of the MUC5B enhancer in Caucasians that results in ~20-fold 
overexpression in the airways (28). The 12% allele frequency in Caucasians is similar to 
the 15% frequency of the sickle hemoglobin allele in areas of hyperendemic malaria, 
consistent with strong positive selection (29). However, constitutive overexpression of 
MUC5B comes at a price because it is a major risk factor for development of interstitial 
lung disease late in life. This is possibly due to epithelial progenitor cell depletion from 
the proteostasis stress of producing large amounts of mucin (30). 
1.1.2.2 Muc5ac 
 In healthy humans but not in mice, MUC5AC is produced constitutively in 
proximal airway epithelial cells. In the distal airways of humans and all of the airways of 
mice, which resemble human distal airways, almost no Muc5ac is detectable (2). Upon 
inflammatory stimuli, such as IL-13, Muc5ac expression in surface epithelial cells goes 
up 40-fold (31). Since Muc5ac is present in many mucoobstructive diseases such as 
asthma, cystic fibrosis and chronic obstructive pulmonary disease, the underlying 
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transcriptional mechanisms leading to its expression better understood. Epidermal 
growth factor receptor (EGFR) signaling have been shown to activate Muc5ac 
expression (32, 33), while forkhead box a2 (FOXA2) suppresses Muc5ac expression 
(34). IL-13 is a potent inflammatory cytokine that drives Muc5ac expression in 
pathologies with type 2 inflammation, such as asthma and allergy. Both IL-13 and EGFR 
induce Muc5ac expression via hypoxia inducible factor-1 (HIF-1) binding at the mucin’s 
promoter. Furthermore, IL-13 induces SAM-pointed domain-containing ETS 
transcription factor (SPDEF) that in turn inhibits FOXA2, leading to up-regulation of 
Muc5ac expression (35). 
 Muc2 is constitutively expressed in the gut, but induced Muc5ac expression 
contributes importantly to helminth defense in the gut (36) and there is now evidence 
that it may help trap helminths migrating through the lungs. It is possible this pathogen 
defense mechanism goes awry in allergic asthma, where inhaled substances such as 
pollens, chitin in insect exoskeletons and fungi, and allergenic proteases falsely signal 
the presence of helminths, resulting in the release of IL-13 from leukocytes (37). Thus, 
an adaptive mechanism that probably evolved to selectively close a limited number of 
airways to protect against helminth migration becomes maladaptive when multiple 
airways close simultaneously in response to inhaled stimuli. Deletion of Muc5ac 
abolishes airway hyperresponsiveness and reduces airway mucus plugging in an allergic 
mouse model, with no impact in mucociliary clearance (38). This suggests that deleting 
Muc5ac could bring relief to mucoobstructive diseases without the detrimental effects of 
failing to clear particles and toxicants. 
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1.2 Mucin exocytosis 
1.2.1 Baseline and stimulated secretion 
1.2.1.1 Baseline secretion 
 Mucin is secreted in the airways at a slow baseline rate and at a high stimulated 
rate. In surface epithelial cells of all intrapulmonary airways of mice and the distal 
bronchi and bronchioles of humans, the rate of baseline mucin secretion matches the rate 
of synthesis in naïve (uninflamed) airways such that there is only minimal intracellular 
mucin (Fig. 1.5, left column) (31). This low level of mucin is difficult to detect, with 
only highly sensitive immunohistochemical stains detecting the mentioned intracellular 
Muc5b throughout the surface epithelium from distal trachea to terminal bronchioles 
(23). With exposure to inflammatory stimuli, mucin production in surface epithelial cells 
can increase 10 to 100-fold but the rate of secretion is not increased, resulting in the 
accumulation of mucins intracellularly (Fig. 1.5, middle column).  
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Figure 1.5. Mucins are secreted both at a low baseline rate and a high agonist-
stimulated rate. The baseline rate of mucin production matches the rate of secretion so 
that intracellular mucin is not visible by histochemical staining (first column). During 
mucous metaplasia, the rate of production exceeds the rate of the baseline secretion such 
that histochemically visible mucin accumulates (second column). The rate of secretion 
can be stimulated by agonists, resulting in the rapid release of stored mucins (third 
column). 
 
 
 
1.2.1.2 Stimulated secretion 
 Upon stimulation by high levels of extracellular agonists such as ATP, 
acetylcholine, or histamine, the rate of airway mucin secretion can be increased 
thousands-fold, resulting in intracellular mucin being released into the airway lumen 
(Fig. 1.5, right column). Davis and colleagues measured this effect using high-speed 
video microscopy in canine airways, finding a 1,760-fold increase in rate of mucin 
secretion after the addition of ATP to the perfusate (39). Similar observations were made 
using the epithelium of normal and cystic fibrosis subjects (40). Individual mucin 
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granules have been observed to release their contents in ~1/10 second, and the released 
mucins absorb several hundred-fold their mass of water to generate mucus in ~1 second 
(41), so the transition from intracellular mucin to extracellular mucus is very rapid after 
stimulation. While the initial burst of stimulated secretion exceeds the baseline rate by 
almost 2,000-fold, it lasts only ~10 seconds. During this initial phase, ~1/2 of the total 
granules that are ultimately released in response to high levels of ATP from naïve canine 
airways are released. The remaining granules are released during a ~2-minute plateau 
phase that is ~38-fold higher than baseline rate. In other words, the stimulation of 
secretion in an inflamed airway that has large amounts of intracellular mucin stored 
leads to the rapid release and swelling of mucin. This rapid release and expansion of 
mucins in inflamed airways leads to occlusion of airways in diseases such as asthma, 
cystic fibrosis and chronic obstructive pulmonary disease (Fig. 1.5, right column).  
 
1.2.2 Steps of exocytosis 
1.2.2.1 Trafficking 
 All cells have a constitutive secretory pathway, and some specialized cells have a 
regulated one. The constitutive secretory pathway functions continuously and is 
necessary for cell viability. The regulated secretory pathway is only found in specialized 
secretory cells. 
Secretory granules need to be transported from the Golgi along actin filaments or 
microtubules to the apical surface where they are tethered to the membrane to be 
exocytosed. Rab GTPases regulate these functions. They belong to the small monomeric 
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Ras-like GTPase superfamily, and are the largest family with over 60 members 
identified in mammals and 11 in yeast (42). Rabs associate with each secretory granule 
in order to regulate formation, transport, tethering, docking and fusion with the plasma 
membrane, and do it by recruiting specific effectors along the vesicle trafficking 
pathway. Rab8, -10 and -14 regulate vesicle trafficking from the trans-Golgi network to 
the plasma membrane for the constitutive secretory pathway, while Rab3 and -27 are 
present in the regulated secretory pathway.  
Rab effectors vary greatly and one Rab can have the ability to bind several 
different effectors. Two microtubule-based motor effectors are kinesin and dynein that 
help transport vesicles towards the plus-end or the minus-end of microtubules (43). 
Other effectors can be tethering proteins that will be explained below, but briefly, they 
help draw the vesicle towards a target membrane. Rabs can change the identity of an 
organelle, for example, a Rab5 containing vesicle belongs to the early endosome 
compartment, while a Rab7 containing vesicle is a late endosome organelle, and the 
exchange of Rab5 for Rab7 promotes the change of organelle identity. The way Rab 
proteins are sequentially recruited and interchanged is a well studied process called the 
Rab cascade.  
1.2.2.2 Tethering 
 Tethering factors for secretory granules can be divided into two main groups, 
homodimeric long coiled-coil proteins and multisubunit tethering complexes (MTC). 
Coiled-coil tethers are large homodimers that can interact with vesicles 200 nm apart. 
MTCs are composed of three to ten subunits and can only reach vesicles up to 30 nm 
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apart (44). It is thought that coiled-coil tethers function in the initial steps of tethering 
because of their ability to form transient, low-affinity interactions, while the MTCs may 
function at a later stage and interact with the soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor (SNARE) machinery, the set of proteins necessary for 
vesicle fusion, because of their ability to bind with different components at the same 
time due to their different subunits (45).  
1.2.2.3 Docking 
 Docking is generally defined as a stage in which vesicles are located at a minimal 
distance from the plasma membrane. While its mechanism is not fully understood, it is 
thought that the SM (Sec1/Munc18) protein Munc18a is involved, as deletion of 
Munc18a results in a reduced number of docked dense core vesicles in chromaffin cells 
(46). Studies using heterozygous mice and overexpression of the protein confirmed these 
findings. Rab proteins have also been suggested as participating in the docking process 
as mutations in their GTP binding site result in accumulation of vesicles in the 
cytoplasm (47). 
1.2.2.4 Priming 
 Once the vesicle is docked to the plasma membrane, the SNARE proteins start 
partially pairing in preparation for fusion. This process is well studied in neurons where 
upon stimulation, the speed of neurotransmitter release was too fast for the multistep 
SNARE fusion process to occur. For regulated exocytosis, regulatory proteins such as 
complexin and synaptotagmin appear to hold in place the partially paired SNARE 
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complex, until intracellular signaling releases this clamp effect and fusion can occur 
(48).  
1.2.2.5 Fusion 
 Fusion takes place once the lipid membranes are in close proximity to each other 
and the SNARE proteins are fully coiled; providing the energy necessary for the lipid 
membranes to fuse. This results in the intracellular vesicle membrane fusing with the 
plasma membrane and releasing its content into the extracellular space (48). 
 
1.2.3 Exocytic machinery 
1.2.3.1 SNAREs 
 SNARE proteins are required for all steps of intracellular vesicular traffic on the 
endocytic and exocytic pathway. They each share a ~65 residue SNARE motif capable 
of assembling with three other SNARE motifs to form a parallel four-helical complex 
(49). The assembly of SNAREs that are located on apposing membranes, forming a trans 
SNARE complex allows membrane fusion.  
SNARE proteins are divided into two main groups, depending on whether they 
have an arginine (R-SNARE) or a glutamine (Q-SNARE) at the midpoint of their 
conserved polar layer, also referred to as the zero layer. These polar interactions at the 
center of the hydrophobic SNARE motif ensure that the four helix bundle is correctly 
assembled. SNAREs were originally classified as v-SNAREs and t-SNARES, based on 
whether they were localized to either the vesicle (v) or target membrane (t), but this 
classification becomes ambiguous for many fusion reactions. VAMPs (vesicle associated 
  19 
membrane proteins) belong to the family of R-SNAREs/v-SNAREs and, as their name 
states, they are located on the vesicle membrane. They contribute to the four helix 
bundle with one SNARE domain. The Syntaxin and SNAP-23 families comprise the Q-
SNAREs/t-SNAREs that are located on the plasma membrane and contribute with one 
and two SNARE helices, respectively, completing the four helix bundle. The authors of 
early in vitro studies suggested that the SNARE proteins constitute the minimal 
membrane fusion machinery. However, these studies did not demonstrate full content 
mixing at a physiological speed, which is indicative of a complete exocytic event along 
with full lipid mixing (50-52).  
1.2.3.2 SM proteins 
 SM proteins are necessary for all types of intracellular vesicular traffic that 
requires SNARE proteins. This evolutionary conserved family of proteins, with sizes 
around 60-70 kDa, drive membrane fusion by interacting with their cognate SNARE 
partners. There are seven isoforms present in mammals (Munc18a, Munc18b, Munc18c, 
Vps33a, Vps33b, Vps45 and Sly1) and four in yeast (Sec1, Vps33, Vps45 and Sly1). 
Munc18a, b, and c are the three mammalian isoforms to have been shown to have a role 
in secretion. Munc18a is expressed in neurons, endothelial cells and endocrine pancreas; 
Munc18b is expressed apically in secretory epithelia and immune cells; and Munc18c is 
ubiquitously expressed. Besides driving vesicle fusion, SM proteins are also responsible 
for chaperoning their cognate Syntaxin to the plasma membrane. In fact, the first report 
of a mammalian SM protein was of Munc18a bound to Syntaxin-1 (Fig. 1.6) (53). Each 
Munc18 protein has higher affinities for specific Syntaxin proteins. These high affinity 
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interactions with Syntaxins allow SM proteins to negatively regulate vesicle fusion as 
they hold their cognate Syntaxin in a closed conformation and prevent further binding to 
the other SNARE proteins prior to priming (54).  
 
 
 
 
 
Figure 1.6. Structure of Munc18a. Left: Structure of Munc18a. Domain 1 is shown in 
blue, domain 2 in green and domain 3 in yellow. Asterisks indicate breaks in the 
structure. Right: Structure of Munc18a-Syntaxin1a complex. Syntaxin1a SNARE 
domain is shown in purple, Habc domain is shown in red. Reprinted from (55). 
 
 
 
Crystal structure analysis revealed that SM proteins contain three domains that 
form an arch shape with a central cavity. Domains 1 and 2 form one arm of the arch 
while the third domain, divided into domains 3a and 3b, completes the other arm (Fig. 
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1.6) (55). Domains 1 and 3a provide a binding site for Syntaxin. A recent study 
generating x-ray structures of the yeast SM protein, Vps33, found that SM proteins can 
also bind the trans-SNARE partner, VAMP, through a groove in domain 3a (Fig. 1.7). 
This means that SM proteins not only function prior to priming and at the last step of 
SNARE complex formation, but rather that SM proteins guide the whole process (56). 
The importance of the SM proteins has been recognized in different organisms. 
Unc-18 was the first SM protein to be identified through a genetic screen in C. elegans. 
Deletion of this protein resulted in a paralyzed phenotype due to severe locomotor 
defects (Uncoordinated) (57). Sec1, the yeast orthologue, was later identified through 
genetic screening for temperature sensitive secretion-defective mutants. Deletion of Sec1 
at the non-permissive temperature resulted in accumulation of intracellular vesicles, 
visible by electron microscopy, indicating a defect in secretion (58). Similarly, mutation 
of the SM orthologue Rop in Drosophila melanogaster results in a secretion defect (59). 
In mammals, deletion of Munc18-1 in mice completely abolished neurotransmitter 
release (60). Together with the SNARE complex, SM proteins constitute the core 
exocytic machinery.  
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Figure 1.7. Working model of exocytosis. The neuronal exocytic machinery is depicted 
here. Munc18, with the help of Munc13 (not shown), undergoes a conformation 
transition to open Syntaxin (from states i to ii). VAMP, the v-SNARE, binds Munc18 
(state iii), and the remainder t-SNARE from the SNAP-25 family joins to form the four 
helix bundle (state v). Full zippering of the SNARE complex leads to membrane fusion 
(states vi and vii). Reprinted from (61). 
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1.2.3.3 Regulatory proteins 
 Besides the core exocytic machinery, there are regulatory proteins that function 
at different steps of exocytosis. The Munc13 family is comprised of five proteins that 
contain a MUN, C1 and C2 domains. The MUN domain aids the transition of Syntaxin 
from a closed conformation to an open conformation and also promotes the assembly of 
the SNARE complex (62). C2 domains bind calcium, phospholipids, and other proteins 
that help in priming, for example. C1 domains bind diacylglycerol and are present in all 
Munc13 proteins except Munc13-4.  
Synaptotagmins constitute a family of sixteen proteins that function as calcium 
sensors. They contain an N-terminal transmembrane domain, a variable linker, and two 
cytoplasmic C2 domains termed C2A and C2B. The C2 domains are responsible for 
binding calcium and curved membranes, which facilitates vesicles and plasma 
membrane interactions (62). 
 
1.2.4 Exocytic machinery in mucin secretion 
1.2.4.1 SNAREs 
 The exocytic machinery responsible for mucin secretion in the airway epithelium 
has not been well defined. The v-SNARE residing in the mucin secretory granule has 
been identified by a group at the University of North Carolina-Chapel Hill as VAMP8 
(Fig. 1.8) (63). We should remember at this point that there are two rates of mucin 
secretion, a slow baseline continuous rate and a high stimulated one. It appears that 
VAMP8 only carries a role in stimulated mucin secretion, but not in baseline secretion. 
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The other SNAREs, the t-SNAREs are still being investigated. Our laboratory identified 
SNAP23 as being one of the t-SNAREs containing two SNARE helices and participating 
in both baseline and stimulated mucin secretion (64). The remaining t-SNARE belongs 
to the Syntaxin family and has not been yet identified.  
 
Figure 1.8. The Secretory Machinery. The SNARE complex is a four helix bundle, 
shown in black, with one helix present on the granule (VAMP), and three present on the 
plasma membrane (SNAP23 and Syntaxin). Munc18 serves as a scaffold for SNARE 
complex assembly. Some components are conserved between baseline and stimulated 
mucin secretion (SNAP23) while others participate only in one (Synaptotagmin 2 in 
stimulated mucin secretion). Other proteins are regulatory (Rab, Munc13). The blue 
component illustrates the signal transduction pathway that activates secretion. 
 
 
 
1.2.4.2 SM proteins 
 The determination of the SM proteins responsible for mucin secretion in the 
airway epithelium constituted the core of my research in the past years and will be 
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described thoroughly in Chapter II. Briefly, our lab identified Munc18b as being largely 
responsible for stimulated mucin secretion using a heterozygous mutant mouse (65). 
Munc18a was later identified by me as the principal mediator of baseline mucin 
secretion using a conditional deletant mouse (Chapter II). 
1.2.4.3 Regulatory proteins 
 One of the first proteins that was identified in the mucin secretory field was the 
priming protein Munc13-2. Munc13-2 knock-out (KO) mice revealed a severe but partial 
defect in both baseline and stimulated mucin secretion (23). The use of a double 
Munc13-2/Munc13-4 KO mouse showed a greater defect in baseline mucin secretion 
and an almost complete defect in stimulated mucin secretion. This suggests that both 
Munc13 proteins have a role in both rates of mucin secretion, with Munc13-2 having a 
predominant one in both rates (unpublished data, Dickey laboratory). 
 The calcium sensor that mediates stimulated mucin secretion in the airway 
epithelium is Synaptotagmin 2 (Syt2), a fast, low affinity calcium sensor (66). Syt2 has 
no apparent role in baseline mucin secretion, and KO mice showed a complete defect in 
stimulated secretion. The calcium sensor mediating baseline mucin secretion is still 
unknown. Other sensors such as Syt7 and Doc2b have been tested but have yielded 
negative results (unpublished data).  
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1.3 Mucus dysfunction in disease 
1.3.1 Allergic asthma 
1.3.1.1 Cell biology of asthma 
 Asthma is a complex disease affecting approximately 300 million people 
worldwide. It is mainly characterized by a type 2 (T2) immunological response. Airway 
type 2 responses are mediated by eosinophils, mast cells, basophils, Th2 cells, innate 
lymphoid cells 2 (ILC2s) and IgE-producing B cells (67). The three hallmarks of allergic 
asthma are eosinophilic inflammation, airway hyperresponsiveness (AHR) and airway 
epithelial mucous metaplasia.  
 
 
Figure 1.9. Cell-cell communication in airway epithelium in asthma. Environmental 
triggers act on airway epithelial cells to initiate responses in multiple cell types that 
result in mucous metaplasia and airway smooth muscle contraction. Reprinted from (68). 
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 The airway epithelium serves as the first barrier for inhaled allergens and 
pathogens. In addition to the mucus protective layer generated by secretory cells, the 
airway epithelium expresses several types of pattern recognition receptors that serve for 
immunological surveillance. Activation of Toll-like receptors (TLRs), such as TLR4, has 
been widely studied and is thought to be one of the key mediators in triggering an 
allergic inflammatory response (69). Stimulation of TLR4 triggers activation of the 
cytoplasmic adaptor proteins myeloid differentiation primary response 88 (MyD88) and 
Toll-interleukin 1 receptor domain-containing adaptor protein (TIRAP) that then leads to 
the release of inflammatory cytokines and chemokines through the nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB) pathway and the interferon beta (IFN-
β)/interferon regulatory transcription factor 3 (IRF3) pathway. Key cytokines released by 
the airway epithelium in allergic inflammation are IL-25, IL-33 and thymic stromal 
lymphopoietin (TSLP) (Fig. 1.9). These, in turn, activate the local network of dendritic 
cells (DCs), mast cells, basophils and ILC2s that produce type 2 cytokines such as IL-13 
and IL-5 (70). IL-13, produced by ILC2s, acts on the airway epithelium by promoting 
mucous metaplasia. Specifically, IL-13 receptor binding leads to Janus kinase (JAK) 
activation and translocation of signal transducer and activator of transcription 6 (STAT6) 
to the nucleus. Once there, STAT6 promotes transcription of the calcium-activated 
chloride channel regulator 3 (CLCA3) and Serpin. CLCA3 then, through autocrine 
signaling, activates the mitogen-activated protein kinase (MAPK) cascade, ending in the 
upregulation of Muc5ac (71). Other receptors present in the airway epithelium include 
C-type lectins that recognize sugar motifs present in allergens, nucleotide-binding 
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oligomerization domain (NOD)-like receptors which contribute to NF-kB pathway 
activation, and protease-activated receptors (PARs) that respond to protease allergens 
(72). Thus the airway epithelium plays an important role in the development of asthma.  
 Mast cells are one of the triggering cells of the inflammatory response in asthma. 
They are activated by cross-linking of IgE receptors and secrete proinflammatory 
mediators such as histamine, leukotriene C4, prostaglandin D2, IL-5 and IL-13. These, 
in turn, promote bronchoconstriction and vasodilation, while IL-13 promotes mucous 
metaplasia.  
Eosinophils, which are highly characteristic of T2 inflammation, secrete 
mediators such as leukotrienes, major basic protein (MBP) and eosinophil peroxidase 
(EPO). Eosinophils secrete cytokines such as IL-13 that promote mucous metaplasia and 
AHR, and growth factors such as TGF-β which induces basement membrane thickening. 
It is important to note that eosinophils are elevated only in a sub-population of patients 
with asthma, and treatments such as inhaled corticosteroids will only work in patients 
with eosinophilic asthma (73). 
 Dendritic cells are antigen-presenting cells that are able to stretch their dendrites 
across the epithelium into the airway lumen to sample inhaled air for antigens. Once 
activated, they migrate to lymph nodes through chemokine signaling, to present antigens 
to naïve T cells. DCs drive T cell differentiation to achieve a Th2 response that is a 
common feature of allergic inflammation. It was initially thought that DCs were able to 
become activated on their own, but studies have shown that they require activation of the 
TLR4 pathway from epithelial cells (74). The now-activated T cells, along with ILC2s, 
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produce IL-13 that acts on secretory cells of the airway epithelium and on airway 
smooth muscle. 
Another key cell type present in asthma is the T cell. As I have mentioned above, 
Th2 cells release IL-13 that drives mucous metaplasia. They also secrete IL-4, that along 
with IL-13, activates B cells that then produce IgE, one of the major immunoglobulins 
responsible for an allergic response, activating mast cells and basophils. T cells also 
release IL-5 that is crucial for eosinophil survival and maturation. IL-5 is also 
responsible for eosinophil stimulation, which drives the eosinophilia observed in the 
lungs. These three cytokines also act on airway smooth muscle, stimulating 
hyperresponsiveness to constrictor stimuli, a feature that interacts with mucus plugging 
and narrow airways. Another important subset of T cells is Th17. These cells 
predominantly produce IL-17 that mainly effects neutrophils as well as airway smooth 
muscle, leading to an increase in airway contractility and priming it for airway 
hyperresponsiveness, but can also stimulate mucin production.    
 Recently, considerable attention has been given to ILC2s and their role in 
asthma. Their role was recognized when mice deficient in RAG (recombinase activated 
gene), which lack mature T cells or B cells, nonetheless generated T2 cytokines and 
eosinophilia upon allergic challenge. ILC2s behave similarly to Th2 cells although they 
are part of the innate immune system and lack T cell receptors. They respond to 
cytokines produced from the airway epithelium, IL-25, IL-33 and TSLP, producing the 
key cytokines of a type 2 profile: IL-13, IL-5 and IL-9 (Fig. 1.9) (75). These cytokines 
promote the recruitment of eosinophils and mucous metaplasia. One recent study 
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showed that ILC2s can represent more than half of the cell population that produces T2 
cytokines, emphasizing their importance in promotion of airway inflammation (76). 
1.3.1.2 The role of mucus in asthma 
 In asthma, the leading cause of death is asphyxiation from airway mucus 
occlusion (Fig. 1.10) (77). As mentioned above, MUC5AC/Muc5ac expression goes up, 
and in some humans, MUC5B expression goes down while Muc5b expression in several 
murine models appears to go up slightly.  The upregulation of mucins is mainly due to 
the inflammatory cytokine IL-13, which is upregulated in more than 50% of patients 
with asthma (71). An increase in EGFR levels detected in asthma patients correlates with 
disease severity (78), and EGFR signaling supports MUC5AC/Muc5ac expression (33). 
 
 
Figure 1.10. Airway mucus occlusion in a human lung from an asthmatic patient. 
Left: Human lung from an asthmatic patient who died from an asthma exacerbation. 
Airway mucus occlusion, airway hyperresponsiveness and inflammation are 
characteristic of acute asthma exacerbations. Center: Lung section with arrows showing 
mucus plugging the airways. Right: Histologic cross section of an airway with its lumen 
completely obstructed by mucus. Reprinted from (79). 
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 Besides changes in expression levels, modifications in glycosylation patterns in 
MUC5B have also been observed. These changes may affect the gel-forming capabilities 
of mucins and the interactions with pathogens or other defense molecules (80). 
Rheological measurements of sputum from patients with asthma showed an increased 
elastic response, indicating increased crosslinking of mucin polymers. Other components 
such as DNA, albumin, and a decrease in protease activity, have been also found in the 
sputum of patients that may contribute to the increased viscoelasticity of mucus (81). 
These abnormalities make it difficult for mucus to be cleared via mucociliary clearance, 
creating airway mucus occlusion. In addition, a recent paper by Bonser and colleagues 
found that when MUC5AC was secreted, it further impaired mucociliary clearance by 
remaining tethered to epithelial secretory cells (82).  
1.3.1.3 Therapeutics 
 Inhaled corticosteroids and β-adrenergic agonists are the two most common 
therapies used in asthma patients. Although they do not target mucus per se, 
corticosteroids aim to reduce the chronic inflammatory component. Their effectiveness 
has been seen as reduced exacerbations, death, and symptoms; improved lung function; 
and decreased eosinophil counts. Despite some efficacy with inhaled corticosteroids, 
there is a small group of patients that show no response to this treatment. Steroid-
resistant patients often have severe disease, but they also demonstrate the heterogeneity 
of asthma. β-adrenergic agonists do not target mucus either as they primarily inhibit 
airway smooth muscle contraction, but they are also required for development of the 
asthma phenotype in a murine model (83). Corticosteroids can inhibit mucous 
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metaplasia after an IL-13 stimulation in human bronchial epithelial cells and that the 
addition of β-adrenergic agonists potentiates this effect (84, 85).  
To target mucus itself, there are two main treatments available currently. One is 
the mucolytic reducing agent N-acetylcysteine, but it is generally not used anymore due 
to its very low efficacy at the tolerable dosage (86). The other treatment is hypertonic 
saline solution, which works by osmotically drawing water into the airway and reducing 
mucus viscosity, making it easier for mucociliary clearance to transport the mucus layer 
(87).  
 
1.3.2 Cystic Fibrosis 
1.3.2.1 Cell biology of cystic fibrosis 
 Cystic fibrosis (CF) is the most common fatal genetic disease in North America 
with a frequency of 1 out of every 2500 people (88). It occurs as a result of mutations in 
the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The CFTR gene 
encodes a cyclic adenosine monophosphate (cAMP) regulated chloride channel with 
expression in the apical membrane of epithelia in the pancreas, intestine, lungs and 
reproductive tract (89). By regulating chloride transport across the plasma membrane, 
CFTR controls the movement of water through the epithelium in order to maintain 
homeostasis (Fig. 1.11). Besides regulating chloride transport across the plasma 
membrane, CFTR also controls bicarbonate secretion. Both of these functions are 
important for mucous membranes, since CFTR dysfunction leads to a dense mucus gel 
with abnormal biophysical properties as a consequence of epithelial surface dehydration 
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and a lowered pH (90). People with CF have an increased risk for lung infections due to 
this thick dense mucus that builds up in the lungs. Accumulation of mucus in the 
pancreas also prevents food and nutrient absorption, and mucus can occlude the bile duct 
in the liver. CFTR mutations are divided into defects in protein synthesis (class I), 
maturation/trafficking (class II), channel gating (class III), altered conductance (class 
IV), and decreased CFTR abundance (class V) (91).  The most common mutation 
belongs to class II, commonly known as ΔF508, carried in almost 90% of the patients on 
at least one allele. 
 
 
Figure 1.11. CFTR deficiency in the airway epithelium leads to dehydrated mucus. 
Left: In a normal airway, CFTR transports chloride and bicarbonate to the airway lumen 
and helps maintain the balance of water. Right: A CFTR dysfunction leads to 
impairment of chloride and bicarbonate transport leading to increased sodium and water 
reabsorption. This results in dehydration of the mucus layer, defective mucociliary 
action, and airway mucus occlusion. Adapted from (92). 
 
 
 
 Mouse models with a CFTR mutation or complete KOs are not good models for 
lung disease due to the mild phenotype resulting from expression of additional chloride 
channels in murine lung epithelium. To overcome that, a mouse model was developed 
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that overexpresses the β subunit of the sodium channel (β-ENaC) in the epithelium of the 
lungs increases airway surface dehydration, resulting in a CF-like phenotype (93). This 
CF-like phenotype exhibits periciliary layer collapse, a slowed mucociliary clearance 
rate, airway mucus occlusion, and neutrophilic inflammation. With bacterial infection, β-
ENaC-overexpressing animals exhibit a temporary rise in bacterial burden upon birth 
that is resolved when reaching adulthood (94). 
1.3.2.2 The role of mucus in CF 
 Although CF affects several organs, pulmonary complications are the major 
cause of mortality in these patients. With the airway dehydration in CF, there is an 
increase in mucus concentration and a reduction in mucociliary clearance. Since there is 
an increase in mucin concentration in the mucus layer, water is drawn from the 
periciliary layer leading to compression and reduction in ciliary activity. Thus, the 
mucus layer adheres to the cell surface of the epithelium, and mucociliary clearance 
eventually stops completely. Mucus stasis progresses into airway mucus occlusion, 
chronic bacterial infection, inflammation and airway tissue damage (90). In addition, the 
lack of bicarbonate in the airway lumen prevents the sequestration of calcium, which 
impedes the mucin from unfolding and hydrating properly (95). 
Studies looking at CF sputum mucin content demonstrate that both MUC5B and 
MUC5AC were increased, with MUC5B being the predominant mucin (96). These 
findings were supported by further immunohistochemical analysis of airway mucus 
occlusion (97) and by another study where Muc5b was found to be the main contributor 
of the phenotypes shown by a CF mouse model (98).  
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1.3.2.3 Therapeutics 
 There are two types of strategy used to target CF. One is to try to correct the 
CFTR dysfunction itself, and the second one is to attack the abnormal physical 
properties of mucus. For the first strategy, a drug developed by Vertex Pharmaceuticals, 
ivacaftor, has shown very promising results. This drug increases the time the channel 
remains open in cell lines expressing a G551D mutation in CFTR, therefore increasing 
CFTR’s chloride and bicarbonate transport. Patients with this mutation treated with 
ivacaftor had reduced pulmonary exacerbations and improved mucociliary clearance 
(99) This class III mutation is only expressed by ~5% of CF patients, but this served as 
an example of how targeting CFTR dysfunction could be effective for treating CF 
patients (100). More recently, ivacaftor has been combined with lumacaftor that corrects 
CFTR misprocessing and increases the number of CFTR proteins that are trafficked to 
the cell surface in ΔF508 mutations. Treatment with this combination is now being used 
in most CF patients (101).  
 To target mucus properties for treatment of CF, mucolytics and hydration therapy 
have been tried, as for asthma. NAC, the reducing agent, shows very little efficacy. 
However, to reduce viscoelasticity contributed by DNA released from inflammatory 
cells, DNase is now used routinely (102). The use of hypertonic saline has been 
surprisingly effective at rehydrating the mucus layer and improving mucociliary 
clearance (103).  
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CHAPTER II 
DISTINCT MUNC18 PROTEINS MEDIATE BASELINE AND STIMULATED 
AIRWAY MUCIN SECRETION 
 
2.1 Rationale 
 The following chapter contains the manuscript that summarizes my work on the 
role of Munc18 proteins in airway mucin secretion. The are several reasons for choosing 
to study Munc18. First, as discussed above, Munc18 belongs to the family of SM 
proteins, and together with the SNARE proteins, they constitute the core exocytic 
machinery, which we thought should be well characterized before analyzing the roles of 
regulatory proteins. Among the SNARE proteins, SNAP23 was being studied in our 
laboratory (see chapter III) but was found to have roles in both baseline and stimulated 
mucin secretion, so did not provide a pathway to dissect baseline and stimulated 
secretion. VAMP8 was partially studied in another laboratory (104), showing a role in 
stimulated secretion, but its baseline role was not tested. The remaining SNARE, 
Syntaxin, was completely unknown. From previous work in our laboratory, it was 
known that Munc18b had a major role in stimulated mucin secretion, but little or none in 
baseline. Identifying the SM protein responsible for baseline secretion would be the first 
example of a selective machinery in baseline secretion. 
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2.2 Introduction 
In mammalian conducting airways, mucus forms a critical barrier that protects 
the lungs from inhaled particles, pathogens and toxicants (2). These foreign substances 
are trapped by mucus, which is swept out of the lungs by ciliary beating into the pharynx 
where it is swallowed. Secreted polymeric mucins, the principal macromolecular 
components of mucus, are large, highly glycosylated proteins that polymerize into linear 
chains and networks (13, 41). Mucins are packaged dehydrated in secretory granules, 
and after exocytosis they interact with several hundred-fold their mass of water to 
expand and generate viscoelastic, gel-like mucus. 
Two polymeric secreted mucins are expressed in the airway epithelium—Muc5b 
and Muc5ac. Mouse Muc5b is expressed constitutively in superficial epithelial cells and 
submucosal glands, and is primarily responsible for mucociliary clearance. Deletion of 
the gene encoding Muc5b in mice results in death from bacterial infection and airway 
obstruction (26). Heterozygous gene deletion results in ~50% reduction in polystyrene 
bead clearance (27), showing that Muc5b is limiting for mucociliary clearance. 
Conversely, an overexpressing allele of human MUC5B is highly prevalent in 
Caucasians and shows evidence of positive selection, probably for its value in protection 
against lung infection even though it is a risk factor for pulmonary fibrosis late in life 
(28, 105). Muc5ac is expressed only at low levels in all airways of naïve (uninflamed) 
mice and in distal airways of humans (2). However, Muc5ac expression rises ~40-fold 
during allergic inflammation (106, 107). Induced Muc5ac expression contributes 
importantly to helminth defense in the gut (36), and may help trap helminths migrating 
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through the lungs (37). In allergic asthma, overexpressed and rapidly secreted Muc5ac 
causes airway mucus occlusion and airflow obstruction (38). 
Mucins are secreted at a low baseline rate and a high agonist-stimulated rate 
(108, 109). Both rates are regulated by the second messengers diacylglycerol and 
calcium acting on the exocytic sensor Munc13-2 (23). Important extracellular agonists 
promoting baseline secretion are ATP and its metabolite adenosine, released 
predominantly from ciliated cells sensing shear stress from airflow during ventilation 
(109-111). These agonists act on heptahelical receptors coupled by G-proteins of the Gq 
subtype to PLC-β that generates the second messengers diacylglycerol and inositol 
triphosphate, with the latter inducing the release of calcium from intracellular stores 
(108). Higher levels of the same agonists can stimulate high rates of mucin secretion 
(39), as can the neural and inflammatory mediators acetylcholine and histamine acting 
on the same pathway downstream of their cognate receptors (38). At high levels of 
intracellular calcium, the fast, low-affinity exocytic calcium sensor Synaptotagmin-2 
promotes mucin secretion (66). Baseline secretion is thought to be primarily responsible 
for clearance of inhaled particles and pathogens, while stimulated secretion can induce 
airway obstruction protectively to trap helminths or pathologically in asthma (37, 38). 
Defects in mucin secretion in SNAP23 and VAMP8 mutant mice implicate the 
highly conserved SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein 
receptors) machinery in mucin exocytosis (64, 104). The SNARE complex is a four-
helix bundle comprised of three helices attached to the target membrane (t-SNAREs) 
and one attached to the vesicle membrane (v-SNARE). Specific binding of these helices 
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confers accuracy and directionality on the fusion reaction, and full coiling provides the 
energy to fuse the lipid membranes. SNARE-dependent vesicle traffic universally 
involves SM (Sec1/Munc18) proteins that promote SNARE complex assembly and help 
prevent off-target interactions (112). Yeast contain four SM proteins, among which the 
exocytic protein Sec1 has evolved into three exocytic Munc18 isoforms in metazoans. 
We previously found, using heterozygous hypomorphic mutant mice (65), that Munc18b 
has a role in stimulated mucin secretion, but were unable to identify a role in baseline 
secretion. Here, by performing a comprehensive analysis of airway epithelial deletants of 
all three Munc18 isoforms in mice, we sought to identify the Munc18 protein(s) 
mediating baseline secretion, to fully characterize the role of Munc18b in stimulated 
mucin secretion, and to test the hypothesis that selective impairment of stimulated 
secretion can protect against airway mucus obstruction in pathophysiologic models.  
 
2.3 Results 
2.3.1 Generation of airway epithelial Munc18 deletant mice 
We had previously found that homozygous mutant Munc18b mice are not viable 
postnatally (65), and others found that homozygous Munc18a (60) and Munc18c (113) 
knockout mice are similarly not viable. Therefore we assembled a panel of conditional 
mutant Munc18 mice by generating a conditional allele of Munc18b that is described 
here (Fig. 2.1 A and 2.2), generating a conditional allele of Munc18c that is described 
elsewhere (114), and obtaining from others a conditional allele of Munc18a (115). 
Crossing conditional Munc18b mice with Zp3-Cre transgenic mice to generate whole 
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animal knockout mice did not yield any Munc18b-/- pups, confirming that Munc18b is an 
essential gene in mice. Munc18b-/- embryos grown in vitro developed to E3.5 at a 
Mendelian ratio, but in vivo, Munc18b-/- embryos at E10.5 were present at less than a 
Mendelian ratio, and at E11.5 there were none (Fig. 2.1 B).  
 
 
Figure 2.1. Generation of Munc18b conditional deletant mice. (A) Exon 1 of the Munc18b 
gene was flanked by two loxP sites (red flags) via homologous recombination. Herpes simplex 
virus thymidine kinase (yellow) was used for negative selection. Zeocin (red) and puromycin 
(green) resistance genes flanked by two loxP (M2) sites (green flags), removed by Cre in 
embryonic stem cells, and a neomycin resistance gene (orange) flanked by two FRT sites (blue 
flags), removed by Flp recombination, were used for positive selection. Exon 1 was removed by 
Cre recombination in mice. (B) Table showing embryos of different genotypes harvested at 
various days of embryonic (E) development after generating a full KO by crossing the mouse in 
(A) to a Zp3-Cre mouse. (C) Litter size after crossing floxed mouse in (A) to a CCSPiCre mouse 
to generate a conditional deletant mouse specific for airway epithelium are compared to their 
floxed littermates (n=50-52 per group). (D) Weight at 3 weeks of age by Munc18b conditional 
deletants and their floxed littermates (n=50-52 per group).  
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Figure 2.2. Sequence around exon 1 of the conditional deletant Munc18b gene. 
Sequencing result of 1788 bp around exon 1 (green) of the mouse shown in Figure 1, A 
after Flp recombination in vivo. Native sequence shown in lower case, introduced 
fragments shown in upper case. LoxP (red), FRT (blue), restriction sites used for cloning 
(yellow highlights), repeats (brown), lost base (grey highlight) and starting codon (red, 
lower case) are indicated. 
 
 
 
Deletion of Munc18b in airway epithelial cells by crossing Munc18bF/F mice 
with CCSPiCre mice (116) yielded Munc18bCCSP-Δ/Δ (hereafter Munc18bΔ/Δ) mice with 
normal litter sizes and weight at 3 weeks compared to Munc18bF/F mice (Fig. 2.1 C and 
D). The efficiency of recombination of CCSPiCre mice at the ROSA26 locus is >99% in 
both airway secretory and ciliated cells (Fig. 2.3 A and B), and occurs occasionally in 
alveolar type 2 secretory epithelial cells as well (Fig. 2.3 C). Histopathologically, the 
lungs of all floxed and single Munc18 isoform airway deletant mice were unremarkable 
by H&E staining, as were the lungs of Munc18a/b and Munc18b/c floxed mice, and 
Munc18a/b double deletant mice (Fig. 2.4 A and B). However, the airways of 
Munc18b/c double deletant mice showed a flattened epithelium with an almost complete 
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absence of airway secretory cells by immunohistochemical staining for club cell 
secretory protein (CCSP) (Fig. 2.4 C), and the lung alveolar regions showed emphysema 
(Fig. 2.4 D). To determine whether these abnormalities reflected dependency on 
Munc18b and Munc18c only during development, we used CCSPCreER mice to induce 
recombination during adulthood (117). Airway secretory cell viability was still impaired 
because CCSP expression was lost two weeks after recombination (Fig. 2.4 E), though 
emphysema was not present (Fig. 2.4 F). 
 
 
Figure 2.3. Efficiency of CCSPiCre recombination. (A) Confocal image of lung sections from 
CCSPiCre; ROSAmTmG/mTmG mice. Lumens of an airway and a vessel, and region of alveoli, are 
indicated. Scale bar=100 m. (B) High magnification image of lung section in (A), showing 
plasma membrane outline. Scale bar=50 m. (C) Confocal image of immunostained lung section 
from same mouse as in (A) using GFP antibody to increase sensitivity of the detection of 
recombination. Arrowheads show type 2 alveolar cells. Scale bar=50 m. 
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Figure 2.4 Double deletion of Munc18b and Munc18c in the airway epithelium. 
Representative lung sections of Munc18b/cF/F (A, B), Munc18b/c/ (C, D) and 
Munc18b/c/-CreER (E, F) mice. A, C and E show airways immunostained with CCSP at 
a low magnification (left column, scale bar=200 m) and at a high magnification (right 
column, scale bar=25 m). B, D and F show alveolar regions stained with hematoxylin 
and eosin. Scale bar=50 m. 
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To determine the normal expression of Munc18 isoforms in the airway 
epithelium and confirm the efficiency of gene deletion, we performed quantitative in situ 
hybridization with riboprobes. Munc18a and Munc18b transcripts were expressed in 
secretory cells at levels several-fold higher than in ciliated cells (Fig. 2.5 A and B), 
whereas Munc18c transcripts were expressed in both cell types at similar levels (Fig. 2.5 
C). All three Munc18 conditional deletant mice showed no significant expression of 
cognate transcripts (Fig. 2.5), and there was no significant difference in transcript 
expression between any of the floxed mice and WT (not shown).        
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Figure 2.5. In situ hybridization of Munc18 isoforms. Representative images of in situ 
hybridization with fluorescent-labeled riboprobes (shown in red), specific for murine 
Munc18a (A), Munc18b (B) and Munc18c (C). Sections are from naïve (uninflamed) 
lungs of floxed and conditional deletant mice. CCSP was used as a secretory cell marker 
(purple) and acetylated tubulin as a ciliated cell marker (green). Graphs show 
quantification of dots per cell type, per genotype, for each probe. Scale bar=30 m. (n=3 
mice per group). (A) Secretory vs ciliated (18aF/F), P=0.03; secretory (18aF/F) vs 
secretory (18a/), P=0.0038; ciliated (18aF/F) vs ciliated (18a/), P=0.0254. (B) 
Secretory vs ciliated (18bF/F), P=0.0012; secretory (18bF/F) vs secretory (18b/), 
P=0.0002; ciliated (18bF/F) vs ciliated (18b/), P=0.0253. (C) Secretory (18cF/F) vs 
secretory (18c/), P=0.0017; ciliated (18cF/F) vs ciliated (18c/), P=0.0004, Student’s 
two-tailed t test. #, P<0.05 between cell types; *, P<0.05 within cell type. 
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2.3.2 Munc18b predominates in stimulated mucin secretion 
Our previous study using heterozygous mutant mice indicated that Munc18b has 
a major role in stimulated mucin secretion (65). To comprehensively analyze Munc18 
function in stimulated secretion, mucin production was first increased (mucous 
metaplasia) in all mutant mice using ovalbumin sensitization and challenge to induce 
allergic inflammation, and then mice were stimulated with the secretagogue ATP to 
induce secretion acutely (Fig. 2.6 A). None of the Munc18 floxed mice showed a 
phenotype in mucous metaplasia or in mucin secretion in this or any subsequent 
experiments. All three Munc18 single conditional deletants had mucin content similar to 
WT mice after the ovalbumin challenge, but the Munc18a/b double deletant had 
significantly higher mucin content (Fig. 2.6 A and B), suggesting a defect in baseline 
secretion that results in mucin accumulation (see below). After ATP exposure, the 
predominant role of Munc18b was confirmed because the conditional deletant secreted 
only ~26% of intracellular mucin (mean value) compared to Munc18b floxed mice that 
secreted ~60% or WT mice that secreted ~52% (Fig. 2.6 C). Munc18a and Munc18c 
deletants secreted as efficiently as their cognate floxed mice or WT mice, while the 
Munc18a/b double deletant secreted ~31%, comparable to the Munc18b single deletant 
(Fig. 2.6 C). 
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Figure 2.6. Stimulated mucin secretion measured by residual intracellular mucin 
content. (A) High-magnification views of representative fields of PAFS-stained 
bronchial airways from mice sensitized and challenged with ovalbumin to increase 
mucin production (OVA+/ATP-, top row), then exposed to aerosolized 100 mM ATP to 
stimulate mucin secretion (OVA+/ATP+, bottom row). Scale bar=20 m. (B) 
Quantification of the volume density (expressed as nl mucin per mm2 basement 
membrane) of intracellular mucin in mice with or without ATP stimulation as in (A) 
(representative experiment of three separate experiments with all genotypes, n=5-8 mice 
per group). 18a/b/ (ATP-) vs WT (ATP-), P<0.0001, vs 18aF/F (ATP-), P<0.0001, vs 
18bF/F (ATP-), P<0.0001, Tukey test. 18b/ (ATP+) vs 18bF/F (ATP+), P<0.0001; 
18a/b/ (ATP+) vs WT (ATP+), P<0.0001, vs 18aF/F (ATP+), P=0.0001, vs 18bF/F 
(ATP+), P<0.0001, Student’s two-tailed t test. (C) The percentage of mucin released for 
each genotype (three independent experiments like those in (B), combined). 18b/ vs 
18bF/F, P<0.0001; 18a/b/ vs WT, P=0.001, vs 18aF/F, P<0.0001, vs 18bF/F, P<0.0001, 
Mann-Whitney test. Box plots, line=median; box=25th-75th percentile; whiskers=5th-95th 
percentile for this and all subsequent figures. *, P<0.05 vs floxed littermate; #, P<0.05 vs 
WT. 
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2.3.3 Munc18a predominates in baseline mucin secretion  
No defect in baseline mucin secretion had been observed in Munc18b 
heterozygous mutant mice (65). This could be due either to the lack of a role of 
Munc18b or to the lack of an obvious phenotype with just a 50% reduction in protein 
expression. To further study baseline mucin secretion, all Munc18 airway deletants were 
examined.  
In naïve (uninflamed) WT mice, the rate of mucin secretion closely matches the 
rate of mucin production such that intracellular mucin does not accumulate and is not 
visible by PAFS histochemical staining. Hence, a defect in baseline mucin secretion can 
be detected as spontaneous mucin accumulation (23, 118). Munc18a deletant mice 
showed significant spontaneous mucin accumulation, indicating a role of Munc18a in 
baseline secretion (Fig. 2.7 A and B). Munc18b and Munc18c deletants showed no 
mucin accumulation. However, Munc18a/b double deletant mice showed a higher level 
of mucin accumulation than Munc18a single deletant mice, indicating an additive effect 
of Munc18a and Munc18b in baseline mucin secretion. Spontaneous mucin 
accumulation was further analyzed by quantitative immunoblotting for Muc5b, which is 
expressed in the airways of naïve mice (23, 26, 85, 106). This confirmed significant 
mucin accumulation in Munc18a deletant mice, a trend towards a small increase in 
Munc18b deletant mice (P=0.09), and an additive effect in Munc18a/b double deletant 
mice (Fig. 2.7 C; Fig. 2.8). Muc5ac is not expressed significantly in the airways of naïve 
mice (26, 85, 106), and was not detected in immunoblots of the lungs of any naïve 
Munc18 deletant mice (not shown).  
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Figure 2.7. Baseline mucin secretion measured by spontaneous intracellular mucin 
accumulation. (A) High-magnification views of representative fields of PAFS-stained 
bronchial airways from naïve mice. Scale bar=20 m. (B) Quantification of the volume 
density of spontaneous intracellular mucin accumulation (n=5-18 mice per group, three 
independent experiments combined). 18a/ vs 18aF/F, P=0.0243; 18a/b/ vs WT, 
P<0.0001, vs 18a/, P=0.0008, Student’s two-tailed t test. (C) Representative 
immunoblot of 50 g of whole lung lysates from naïve mice probed for Muc5b. (D) 
Densitometric analysis of immunoblot shown in (C) derived from standard curve (Fig. 
S4) (AU, arbitrary units) (n=5-7 mice per group). 18a/ vs WT, P=0.0079; 18a/b/ vs 
WT, P=0.0025, Mann-Whitney test. *, P<0.05 vs floxed littermate; #, P<0.05 vs WT. 
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Figure 2.8. Muc5b immunoblot of naïve Munc18 conditional deletant mice 
excerpted in Figure 2.7. (A) Agarose gel electrophoresis and PVDF membrane transfer 
developed with ECL and imaged using X-ray film of lung lysates from naïve WT and 
Munc18 conditional deletant mice probed for Muc5b. Labels on gel show genotype and 
protein amount loaded. Standard lanes come from a Munc18a/ lung homogenate. (B) 
Band intensity was determined for a range of standard loading amounts and the curve 
was fitted using a 4-parameter logistic curve.  
 
 
 
To examine granule morphology by electron microscopy and stereological 
analysis, mice were lightly stimulated with IL-13 so that mucin granules were readily 
visible in WT mice (Fig. 2.9 A). Munc18a/b double deletant mice showed an increase in 
surface-to-volume density of granules (Sv, Fig. 2.9 B), indicating smaller granules with 
a lower ratio of surface area to volume. However, there was no change in volume density 
of granules per volume density of cells (Vv, Fig. 2.9 C). Together, these findings 
indicate that the cells from Munc18a/b double deletant mice had an increased number of 
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smaller granules. In addition, mucin granules in Munc18a/b double deletant mice were 
also found to be more electron-dense (Fig. 2.9 D). 
 
 
Figure 2.9. Assessment of granule size, number and density by electron microscopy. 
(A) Representative EM images of secretory cells of WT and Munc18a/b/ mice treated 
with a low dose (0.2 g) of IL-13. Arrow – atypical mitochondrion (31); open arrowhead 
– lucent mucin granule with dense core; filled arrowhead – condensed mucin granule 
with dense core. Scale bar=1 m. (B) Sv (surface density related to volume density) of 
granules measured by stereology, with greater Sv indicating smaller size. WT vs 
18a/b/, P<0.0001, Student’s two-tailed t test. (C) Vv (volume density of granules 
related to volume density of cells). (D) Frequency distribution of electron density of 
mucin granules based on a 0 to 255 relative scale (only values between 0-150 are 
shown). WT vs 18a/b/, P<0.0001, Kolmogorov-Smirnov test. #, P<0.05 vs WT. 
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2.3.4 Deletion of Munc18a or Munc18b does not impair mucociliary clearance  
To rule out the possibility that spontaneous mucin accumulation was due to an 
increase in mucin expression resulting from an inflammatory response in any of the 
deletants, mRNA expression was analyzed by qRT-PCR in Munc18a and Munc18 single 
deletant mice and Munc18a/b double deletants. There was no significant increase in 
expression of Muc5ac or Muc5b in any of the conditional deletants (Fig. 2.10 A).  This 
absence suggested that mucociliary clearance function was preserved, preventing lung 
infection and inflammation that might induce mucin gene upregulation. To further test 
these inferences, several additional studies were performed. First, lung lavage fluid was 
obtained for measurement of leukocytes, which is a sensitive indicator of inflammatory 
status. There was no difference in total cell number or fractional representation of any 
leukocyte subset in either of the Munc18a or Munc18b single deletant mice compared to 
WT or floxed littermate mice (Fig. 2.10 B). However, the double deletant mice showed a 
small but significant increase in neutrophil number. Next, polystyrene beads were 
instilled into the lungs to measure their clearance by mucociliary transport. There was no 
difference in the fraction of beads cleared by Munc18a or Munc18b deletant mice 
compared to WT (Fig. 2.10 C). Last, the lung microbiome was interrogated by qPCR 
and sequencing of 16S ribosomal RNA. There was no significant difference in the 
quantity (Fig. 2.10 D) or composition (Fig. 2.10 E) of bacteria present in the lungs of 
Munc18 single or double deletant mice compared to WT or floxed littermate mice.  
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Figure 2.10. Assessment of mucin gene expression, inflammation, mucociliary 
clearance function and bacterial infection in Munc18 conditional deletant mice. (A) 
qRT-PCR of lung tissue for Muc5b and Muc5ac relative to -actin (n=5 mice per group). 
Mice treated with IL-13 are plotted for comparison. (B) Total inflammatory cell numbers 
from the lung lavage fluid of naïve mice (n=5-9 mice per group). (C) Fluorescent 4 m 
polystyrene microspheres were instilled into the lungs, and microspheres present in the 
lungs were counted at the time of instillation and after 30 min (n=5-8 mice per group). 
WT (0 min) vs WT (30 min), P=0.0127, vs 18a/ (30 min), P=0.0295, vs 18b/ (30 
min), P=0.0087, Mann-Whitney test. (D) qPCR of lung tissue for copies of bacterial 16S 
per 10 ng of total DNA (n=7 per group) (E) Principal components analysis of bacterial 
communities using ribosome gene 16S rDNA gene sequencing (n=7 per group). #, 
P<0.05 vs WT. 
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2.3.5 Deletion of Munc18b protects mice against airway obstruction in a model of 
allergic asthma 
Increased mucin production followed by stimulated secretion causes airway 
lumenal mucus occlusion and airflow obstruction in asthma (2, 38). We hypothesized 
that deletion of Munc18b in airway secretory cells would protect against this 
pathophysiology. To test this, we first performed a pilot study in a WT mouse with IL-13 
instilled intrapharyngeally to induce mucous metaplasia and then exposed to a 
methacholine aerosol to stimulate mucin secretion. We measured the occlusion of 
airways throughout the lungs at 500 µm intervals as a fraction of cross-sectional airway 
area, and found that the right caudal lobe had the highest fractional occlusion (Fig. 2.11 
A). We next compared fractional occlusion in the right caudal lobe between Munc18b 
floxed and deletant mice and found a significant reduction (~50%, mean values) in the 
deletant mice (Fig. 2.11 B). We then performed a definitive study comparing the sum of 
the area of lumenal mucus in the right caudal lobe at 1 mm intervals together with 
measurement of lung mechanics (Fig. 2.12). Munc18b deletant mice showed a ~62% 
reduction (mean values) in lumenal mucus area compared to Munc18b floxed mice, 
similar to the ~37% reduction in Muc5ac knockout mice, whereas Munc18a deletant 
mice showed no reduction (Fig. 2.12 B).  
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Figure 2.11. Assessment of airway mucus occlusion. (A) Distribution of airway mucus 
occlusion throughout the lung lobes. A WT mouse was treated with IL-13 (2 g daily for 
4 days) to induce mucin production, and then stimulated with aerosolized 150 mM (30 
mg/ml) MCh to stimulate mucin secretion. Lobes were sectioned every 500 m, stained 
with PAFS, and a ratio of the area of mucus to the area of lumen (fractional occlusion) 
was obtained. Right caudal lobe vs left lobe, P=0.0043, vs right cranial lobe, P=0.0002, 
vs right middle lobe, P=0.0008, vs accessory lobe, P=0.0025, Tukey test. (B) Munc18 
deletant and floxed littermate mice were treated as in (A), and fractional occlusion in the 
right caudal lobe was determined. (n=7-8 mice). 18b/ vs 18bF/F, P=0.0336, Student’s 
two-tailed t test. *, P<0.05. 
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Figure 2.12. Airway mucus occlusion and airway hyperreactivity of Munc18b 
conditional deletant mice in an allergic asthma model. (A) Representative cross-
sections of airways fixed with methacarn to preserve mucus volume and stained with 
PAFS. Mice were treated with IL-13 to induce mucin production and then stimulated 
with aerosolized 150 mM methacholine (MCh) to stimulate mucin secretion and smooth 
muscle contraction. Scale bar=50 m. (B) Cross-sectional area of lumenal mucus in the 
right caudal lobe measured at 1000 m intervals. (n=5-9 mice per group, representative 
experiment, >100 airways per group quantified). 18b/ vs 18bF/F, P=0.0002; Muc5ac-/- 
vs 18bF/F, P=0.0378, Student’s two-tailed t test. (C) Total respiratory system resistance 
(Rrs) at increasing doses of nebulized MCh in mice treated with or without IL-13 (n=6-
14 per group, three independent experiments combined). Line, mean; error bar, SEM. 
(D) Fold-change Rrs at the highest dose of nebulized MCh (30 mg/ml) from (C). Each 
genotype is normalized to its own baseline measured with nebulized saline. 18b/ vs 
18bF/F, P=0.0018; Muc5ac-/- vs 18bF/F, P=0.0044, Student’s two-tailed t test. *, P<0.05 vs 
floxed littermate. Bar, mean; error bar, SEM.  
 
 
 
Exposure to methacholine induces resistance to airflow due to a combination of 
smooth muscle contraction (bronchoconstriction) and mucus obstruction (38). An 
augmented response to methacholine (airway hyperresponsiveness) is a sensitive 
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indicator of asthmatic airway dysfunction. WT mice with mucous metaplasia induced by 
IL-13 and exposed to increasing concentrations of aerosolized methacholine showed 
increased respiratory system resistance compared to naïve WT mice (Fig. 2.12 C and D). 
Munc18aF/F, Munc18bF/F, and Munc18aΔ/Δ mice with mucous metaplasia were similar to 
WT mice, but Munc18bΔ/Δ and Muc5ac-/- mice with mucous metaplasia were highly 
protected from airway hyperresponsiveness to methacholine (Fig. 2.12 C and D). 
 
2.3.6 Deletion of Munc18b protects mice against airway mucus occlusion and 
parenchymal emphysema in a model of cystic fibrosis  
In cystic fibrosis, an inherited defect in transepithelial anion and water transport 
causes the formation of mucus that is excessively concentrated, viscoelastic and 
adhesive (119-121). Mucus accumulates because its excessive viscoelasticity impedes 
clearance by ciliary beating and its adhesivity results in the formation of airway mucus 
plaques. These in turn, lead to infection and inflammation that cause progressive lung 
disease. In mice, deletion of the anion transporter, CFTR, does not result in lung disease 
because of the presence of alternative mechanisms of anion transport, but transgenic 
overexpression of the beta subunit of the epithelial Na+ channel (ENaC) results in 
concentrated mucus leading to lung disease that resembles human cystic fibrosis (93).  
To test whether stimulated mucin secretion contributes to pathophysiology in this 
model, we crossed Munc18b deletant mice with βENaC-Tg mice (Fig. 2.13 A). Mucus 
occlusion in βENaC-Tg mice was reduced by ~66% (mean values) by deletion of 
Munc18b in the airway (Fig. 2.13 B). Emphysema measured as equivalent mean 
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diameter (D2) was increased ~86% in βENaC-Tg-Munc18bF/F mice compared to 
Munc18F/F mice as previously described for the βENaC-Tg (93) (Fig. 2.13 C). This 
increase was attenuated by ~22% by deletion of Munc18b in the airway (Fig. 2.13 C). 
However, lung neutrophilic and eosinophilic inflammation present in βENaC-Tg-
Munc18bF/F was not reduced by Munc18b deletion (Fig. 2.13 D). 
 
 
Figure 2.13. Airway mucus occlusion and emphysema of Munc18b conditional 
deletant mice in a cystic fibrosis-like model. Munc18bF/F and Munc18b/ mice were 
crossed or not to -ENaC-overexpressing transgenic (ENaC) mice. (A) Representative 
transverse left lung sections stained with AB-PAS. Scale bar=300 m. (B) Cross-
sectional area of lumenal mucus was quantified. (n=8-16 mice per group). ENaC-18b/ 
vs ENaC-18bF/F, P=0.0013, Mann-Whitney test. (C) Emphysema was assessed as the 
equivalent mean diameter, D2. (n=8-16 mice per group). ENaC-18b/ vs ENaC-18bF/F, 
P=0.0009, Student’s two-tailed t test. (D) Total inflammatory cell numbers from lung 
lavage fluid (n=8-16 mice per group). *, P<0.05 vs floxed littermate. 
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2.4 Discussion 
Here, we have performed a comprehensive analysis of the function of Munc18 
proteins in a polarized epithelial cell specialized for apically directed regulated secretion. 
Our central finding is that baseline and stimulated secretion are predominantly mediated 
by different Munc18 proteins, with Munc18a having the major role in baseline secretion, 
Munc18b having the major role in stimulated secretion, and Munc18c having no 
apparent role. This finding has implications for understanding the cell biology of 
regulated secretion in polarized cells and for manipulating the exocytic machinery of the 
airway epithelium therapeutically to alleviate mucus dysfunction. 
Regarding cell biology, Munc18b has been described previously by us and others 
as mediating apical secretion in polarized epithelial cells (65, 122, 123). Munc18a has 
been studied primarily for its role in synaptic vesicle release from neurons (60, 124, 
125), but other regulated exocytic systems where Munc18a has been reported to function 
include vascular endothelial cells (126) and acrosomal exocytosis in spermatozoa (127). 
In airway epithelium, Munc18a was reported to modulate the conductance of the apical 
anion channel CFTR (128), but a role in vesicular transport was not described. Munc18a 
and Munc18b have been reported to cooperate in regulated exocytosis of insulin-
containing granules of pancreatic islet cells (129, 130) and cytolytic granules of natural 
killer cells (131) in response to different signaling pathways. Prior reports that Munc18a 
and Munc18b both participate in mast cell degranulation appear to have been in error, 
with Munc18b having an exclusive role as we recently described (114). Thus, the current 
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work is the first report, of which we are aware, of two different Munc18 proteins 
mediating different rates of secretion in response to the same signaling pathway. 
Munc18c has been proposed to mediate basolateral secretion in polarized 
epithelial cells (132, 133), consistent with the lack of effect of Munc18c deletion in 
apical regulated secretion in our system (Fig. 2.6 and 2.7). A role for Munc18c in 
stimulated exocytosis has been described in non-polarized cells, such as translocation of 
glucose transporters in adipocytes (134), but not in in polarized epithelia. The cellular 
lethality induced by simultaneous deletion of both Munc18b and Munc18c in airway 
epithelial cells (Fig. 2.4) suggests that the predominant function of Munc18c is in 
constitutive secretion because that is an essential cellular function. We hypothesize that 
Munc18c function is rescued in the single airway deletant mouse by ectopic function of 
Munc18b. This hypothesis is consistent with the cellular viability of airway epithelial 
cells in double Munc18a/b mice (Fig. 2.6 and 2.7) because regulated secretion is not a 
cell-autonomous essential function. Whether Munc18c mediates constitutive secretion at 
both the apical and basolateral surfaces in airway epithelial cells or functions exclusively 
at the basolateral surface is not known. 
Since Munc18 proteins partner with specific Syntaxins t-SNAREs (65), our 
findings here suggest that the exocytic SM-SNARE machinery is mostly different 
between baseline and stimulated mucin secretion. This inference is supported by the role 
of the v-SNARE VAMP8 predominantly in stimulated secretion (104), even though 
SNAP23 functions in both processes (64). What might be the adaptive value of utilizing 
different exocytic machines for baseline and stimulated secretion rather than utilizing a 
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single machine capable of running at different rates? In view of the differing roles of 
baseline and stimulated mucin secretion in mucociliary clearance and airway occlusion 
(38), and the differing roles of Muc5ac and Muc5b in helminthic and microbial defense 
(26, 36), several plausible possibilities exist. These include different exocytic machines 
acting on small immature granules in baseline secretion to minimize the chance of 
airway occlusion, and on large mature granules in stimulated secretion to maximize the 
chance of occlusion. This might occur by exchanging VAMP proteins during granule 
maturation, by analogy with Rab conversion during progression from early to late 
endosomes (135). Another possibility is that Muc5ac and Muc5b are packaged 
separately during exit from the trans-Golgi network (136), with different exocytic 
machines acting on secretory granules containing either secreted mucin. This last 
possibility is supported by the apparent segregation of MUC5AC and MUC5B 
extracellularly and intracellularly in human asthmatic airways (82). Further studies 
colocalizing vesicular components of the exocytic machinery such as VAMPs and 
Synaptotagmins with different secreted mucins will be required to resolve these 
questions. The fact that secretory granules visualized by EM in Munc18a/b double 
deletant mice are smaller and denser than granules in WT mice (Fig. 2.9) suggests that 
these SM proteins also mediate homotypic fusion between granules during post-Golgi 
maturation, and that mucins decondense to some degree during granule maturation. 
Importantly, the existence of two different exocytic machines in airway secretory 
cells affords the possibility to molecularly target the pathologic consequences of 
stimulated mucin secretion without compromising the critical protective clearance 
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function of baseline mucin secretion. While the fundamental pathophysiologic processes 
in allergic asthma and cystic fibrosis are mucin hyperproduction and impaired anion 
transport, respectively, stimulated mucin secretion contributes to airway occlusion in 
both diseases as indicated by our prior (38) and current studies in mouse models of 
allergic asthma (Fig. 2.12) and cystic fibrosis (Fig. 2.13). To fully appreciate the 
contribution of stimulated secretion to airway mucus occlusion, it is important to 
recognize several features of mucin biology. First, the production of mucins, particularly 
of Muc5ac, can be greatly increased by inflammatory signaling, resulting in the filling of 
airway epithelial secretory cells with large amounts of mucin contained within secretory 
granules (Fig. 2.6). If secretion is not stimulated, the stored mucins are slowly released 
and cause only minimal mucus occlusion (38). Second, stimulated secretion can result in 
the explosive exocytic release of mucin granule contents within seconds (39), and the 
massive extracellular swelling of the released mucins by absorbing several hundred-fold 
their mass of water occurs in less than a second (41, 137). Thus, the area of the airway 
cross-section occupied by intracellular mucin is only a small fraction of that occupied by 
fully hydrated extracellular mucus, and the extracellular expansion of mucin volume 
within such a short time frame are key determinants of pathophysiology. In large 
proximal airways, rapid release of stored mucins from surface epithelial cells is unlikely 
to completely occlude the airway lumen, and may have adaptive value in promoting the 
trapping of particles and pathogens for clearance, as described for submucosal glands 
(138, 139). However, in small distal airways, rapid massive mucin release can 
overwhelm clearance mechanisms, resulting in airway lumenal occlusion (38) (Fig. 2.12 
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and 2.13). The adaptive value of small airway occlusion in the stimulated secretion of 
metaplastic epithelial cells may be to trap helminths migrating through lungs (37), a 
hypothesis being tested by us and others. In allergic asthma, IL-13 plays a central role in 
increased mucin production, as it does in helminth infection, and rapid secretion can be 
induced by acute inflammatory mediators such as acetylcholine and histamine (37, 38). 
In cystic fibrosis, increased mucin production is more modest (119), and the role of 
secretagogues in small distal airways is less well studied. However, the stimulation of 
secretion from submucosal glands is critical to mucus dysfunction in a pig model of 
cystic fibrosis (119), and the stimulation of mucin secretion from surface epithelial cell 
by acetylcholine from neurons or ATP from leukocytes or epithelial cells could 
contribute to mucus occlusion in small airways.       
  Mucus occlusion was significantly reduced by deletion of Munc18b in airway 
epithelial cells in both of the mouse models of airway disease we tested. In the allergic 
asthma model, reduction of mucus occlusion was shown to result in improvement of 
lung mechanics (Fig. 2.12 C and D). In the cystic fibrosis model, while the emphysema 
that occurs secondary to mucus occlusion was also mitigated (Fig. 2.13 A and C), 
neutrophilic and eosinophilic inflammation was not reduced (Fig. 2.13 D), similar to 
what occurred upon treatment with aerosolized hypertonic saline solution in that model 
(140). Deletion of Munc18b in airway epithelium did not result in any abnormalities of 
lung structure, particle clearance, inflammation, or bacterial infection (Fig. 2.10). 
Therefore, targeting the stimulated exocytic machine with small molecules or RNA 
silencing technologies in human subjects might be free of intrinsic adverse 
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consequences. Whether the trapping of helminths during migration through the lungs 
might be impaired by Munc18b deletion is an area of our active investigation, but 
helminth infestation is not a common problem in developed countries.   
 
2.5 Methods 
2.5.1 Mice  
C57BL/6J (catalog no. 000664), C57BL/6-Tg(Zp3-cre)93Knw/J (catalog no. 
003651), Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J (catalog no. 007576) and 
B6N.129S6(Cg)-Scgb1a1tm1(cre/ERT)Blh//J (catalog no. 016225) mice were purchased from 
The Jackson Laboratory. We obtained Munc18a conditional deletant mice from Dr. 
Matthijs Verhage (U. Amsterdam) (115), Munc18c conditional deletant mice from Dr. 
Roberto Adachi (U. Texas MD Anderson Cancer Center) (114) and CCSPiCre 
(Scgb1a1tm1(icre)Fjd) mice from Dr. Francisco DeMayo (NIEHS) (116). -ENaC-
C57BL/6-Tg mice (93) were crossed to Munc18b conditional deletant mice at the 
University of North Carolina at Chapel Hill. 
In the Munc18a conditional deletant, exon 2 of the gene is flanked by two loxP 
sites and Cre recombination induces a frameshift resulting in a nonsense codon and 
absence of protein (115). In the Munc18c conditional deletant, exon 1 is flanked by two 
loxP sites and Cre recombination removes the start codon (114). To generate Munc18b 
conditional deletant mice, we built a targeting vector to insert two loxP sites to flank 
exon 1 (Figure S1) by homologous recombination. Upstream of exon 1, the zeocin and 
puromycin resistance genes flanked by two loxP sites (M2) were inserted, and 
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downstream of exon 1, the phosphoglucokinase promoter-neomycin resistance gene 
(PGK-neo) resistance gene flanked by two Flp recognition target (FRT) sites was 
inserted. The herpes simplex virus thymidine kinase gene was introduced outside the 
homology arms for negative selection. This vector was electroporated into 129S6:B6 
embryonic stem cells; after 24 h cells were selected using (1-(2-deoxy-2-fluoro-1-D-
arabinofuranosyl)-5-iodouracil), puromycin and G418. Of 84 surviving clones, one 
correctly targeted clone was chosen for subsequent manipulation. The puromycin 
resistance gene was removed in vitro by electroporation of a circular CMV-Cre plasmid 
into the positive clone. Cells were plated at low density (2.5 x 105 to 2.0 x 104 cells/ml), 
and individual clones were transferred to 96-well plates. Duplicate plates were prepared, 
and one plate selected on puromycin. Of the 19 subclones that did not survive puromycin 
selection, one clone was shown to have correct targeting to remove the puromycin 
resistance gene by PCR. This clone was used for injection into B6(Cg)-Tyrc-2J/J 
blastocysts. The 8 chimeric males generated were crossed to B6(Cg)-Tyrc-
Gt(ROSA)26Sortm1(FLP1)Dym/RainJ (The Jackson Laboratory, catalog no. 009086) to 
remove PGK-Neo and establish our floxed line. We then crossed the Munc18b floxed 
mouse with C57BL/6-Tg(Zp3-cre)93Knw/J (catalog no. 003651) to generate full animal 
KOs (Figure 1, B) or with CCSPiCre mice for specific deletion in the airway epithelium. 
All our lines were crossed with C57BL/6J mice for 10 generations.  
Genotypes of Munc18b mutant mice were determined by PCR of genomic DNA 
with primers #7 (AAGGCGGTGGTAGGGAAAGT) and #64 
(CAGTTGGTCAAATTCAAGTGCTC) to differentiate between the conditional (F; 
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1075 bp) and WT (+; 931 bp) alleles. Munc18a and Munc18c were genotyped as 
previously described (114). The presence of Zp3-cre was determined by PCR with 
primers ZpCre 5’ (GCGGTCTGGCAGTAAAAACTTC); ZpCre 3’ 
(GTGAAACAGCATTGCTGTCACTT); IntControl 5’ 
(CTAGGCCACAGAATTGAATTGAAAGATCT); IntControl 3’ 
(GTAGGTGGAAATTCTAGCATCATCC), that give a 324 bp internal control band and 
a 100 bp band from the transgene. The presence of conditional CCSPiCre was determined 
by PCR with primers CC10-iCreR (GAGATGTCCTTCACTCTGATTC); CC10-iCreF 
(TCTGATGAAGTCAGGAAGAACC); FJD13 
(TGCCAGAGATTGTTCTAGAAAACAA) and FJD14 
(GGCACAATGATGTTAATGACGTAAA), that give a 1 kbp internal control band and 
a 0.5 kbp band from the transgene. Genotyping for the -ENaC-Tg mice was performed 
as previously described (93). 
For CreER induction, five doses of 6 mg of tamoxifen (T5648, MilliporeSigma) 
dissolved in corn oil (C8267, MilliporeSigma) were injected into adult mice every other 
day intraperitoneally (i.p.). Mice were harvested two days after the last dose. Mice of 
both sexes were used in all experiments, ranging from 6-32 weeks of age.  
 
2.5.2 Immunohistochemistry  
Lungs were inflated and fixed with 10% neutral buffered formalin (NBF) for 24 
h at 4°C and then embedded in paraffin. Lung sections were cut into 5-m transverse 
sections, deparaffinized, exposed for 10 min to 3% H2O2 in 90% methanol and then 
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heated for 10 min in 10 mM sodium citrate, pH 6.0, for antigen retrieval. Tissue sections 
were blocked with 5% donkey serum (017-000-121, Jackson ImmunoResearch) for 1 h 
at room temperature and then incubated with goat anti-CCSP (a gift from Dr. Barry 
Stripp, Cedars-Sinai, 1:2000) diluted in blocking solution at 4°C overnight. Secondary 
antibody-horseradish peroxidase (HRP)-labeled donkey anti-goat (705-035-003, Jackson 
ImmunoResearch, 1:500) was incubated for 1 h at room temperature. Tissue sections 
were then washed with PBS, dehydrated and mounted with VectaMount (Vector 
Laboratories).  
 
2.5.3 In situ hybridization and immunofluorescence  
In situ RNA detection was performed using the RNAscope detection kit 
(Advanced Cell Diagnostics, Hayward, CA) according to the manufacturer’s 
instructions. Briefly, lungs were inflated and fixed with 10% NBF for 30 h at room 
temperature and then embedded in paraffin. Tissue blocks were cut into 5-m sections, 
deparaffinized, and pretreated with heat and protease before hybridization with the target 
oligonucleotide probes: murine Munc18a (Probe-Mm-Stxbp1, 521961), Munc18b 
(Probe-Mm-Stxbp2, 536201) and Munc18c (Probe-Mm-Stxbp3, 536191). The positive 
control probe was Ppib (peptidylprolyl isomerase B, 313911) and the negative control 
probe was DapB (4-hydroxy-tetrahydrodipicolinate reductase from Bacillus subtilis, 
310043). Preamplifier, amplifier and fluorescent-labeled oligonucleotides were then 
hybrized sequentially. RNAscope signal was imaged at the axial bronchus, between 
lateral branches 1 and 2 (118). Images were acquired using a confocal microscope 
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(A1plus, Nikon) with a 40× NA 1.3 objective lens. For analysis, the number of dots per 
secretory or ciliated cell were counted using ImageJ (141). Since dot intensity represents 
transcript amount, brighter and/or bigger dots were counted twice. More than 70% of the 
dots were scored as singlets. Scoring all the doublets as singlets can only result in a 4% 
error. 
Immunofluorescence was performed using antibodies against goat CCSP 
(1:2000) and mouse acetylated tubulin (T6793 MilliporeSigma, 1:2000). Secondary 
antibodies were species-specific donkey anti-IgG coupled with Alexa Fluor 488 
(A21202) and Alexa Fluor 647 (A21447) (1:1000, Invitrogen).  
 
2.5.4 Airway epithelial mucin content by PAFS staining and image analysis  
Mucous metaplasia was induced in the airways of mice by sensitizing mice to 
ovalbumin (OVA) (20 μg OVA Grade V, 2.25 mg alum in 0.9% saline, pH 7.4; 
MilliporeSigma) administered by i.p. injection once weekly, for 3 weeks. Sensitized 
mice were exposed for 20 min to an aerosol challenge of 2.5% (wt/vol) OVA in 0.9% 
saline supplemented with 0.02% (vol/vol) antifoam A silicon polymer (MilliporeSigma) 
daily for five days via an Aerotech II compressed gas nebulizer (Biodex, New York) in 
the presence of room air supplemented with 5% CO2. Three days after the last OVA 
aerosol exposure, half of the mice in each group were exposed for 10 min to an aerosol 
of 100 mM ATP (MilliporeSigma) in 0.9% NaCl to induce mucin secretion, then 
sacrificed after 20 min. Lungs were harvested, inflated and fixed in 10% NBF, 
embedded in paraffin and sectioned into a single transverse 5 m cut of the axial airway 
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of the left lung, between the lateral branches 1 and 2 (118). Sections were 
deparaffinized, rehydrated, and then stained with periodic acid fluorescent Schiff reagent 
(PAFS). Images were acquired using an upright microscope (Olympus BX 60) with a 
40× NA 0.75 objective lens and intracellular mucin was measured around all the 
circumferential section of the axial bronchus using ImagePro (Media Cybernetics, 
Bethesda, MD). Data are presented as the epithelial mucin volume density, signifying 
the measured volume of mucin overlying a unit area of epithelial basal lamina, derived 
as described (31). Images were analyzed by investigators blinded to mouse genotype and 
treatment.  
 
2.5.5 Agarose gel Western blot for mucin  
Lungs were perfused by intracardiac injection of 2 ml PBS until blanched, then 
homogenized in 1 ml of 6 M guanidinium buffer containing protease inhibitors and 
incubated for two days at 4°C. Lysates were centrifuged at 19,000 g and the supernatants 
were then dialyzed overnight at 4°C against PBS in Slide-A-Lyzer 2K MWCO 3 ml 
cassettes (Thermo Fisher Scientific). Protein concentrations were determined using a 
bicinchoninic acid protein assay kit (Thermo Fisher Scientific) and then the samples 
were incubated with 20 Kunitz DNase (LS002139, Worthington) for 15 min at 37°C and 
reduced with 10 mM DTT (MilliporeSigma) for 10 min at 95°C in loading buffer (5% 
glycerol, 0.1% SDS, 0.0025% bromophenol blue, 0.6 M urea, 10 mM Tris-HCl, 0.5 mM 
EDTA, pH 8). Samples were electrophoresed through a 0.8% agarose/0.1% SDS 
hydrogel, and the gel was then soaked in 10 mM DTT for 20 min, then the samples were 
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transferred by vacuum onto a PVDF membrane. Membranes were washed in PBS and 
blocked with 5% nonfat milk in PBS/0.05% Tween before probing with lectin UEA-1 
conjugated to HRP (1:1000, L8146, MilliporeSigma) in blocking solution to detect 
fucosylated Muc5ac (118), or with monoclonal antibody MDA-3E1 raised by us against 
peptide TTCQPQCQWTKWIDVDYPSS in blocking solution (1:1500) to detect Muc5b 
(64). Secondary antibody for Muc5b was goat anti-mouse conjugated to HRP (1:5000, 
Thermo Fisher Scientific), and the chemiluminescence signal was detected with ECL 
Western Blotting Substrate (Thermo Fisher Scientific). Relative protein amounts were 
determined for each sample using ImageJ (NIH) against a standard curve run for each 
gel (Figure S4). 
 
2.5.6 Electron microscopy and stereology  
Slight mucous metaplasia was induced in mice with one dose of 0.2 μg of IL-13 
instilled intrapharyngeally on day 1 of the experiment in order to achieve optimal 
visualization of mucin granules. Mice were then anesthetized and sacrificed on day 5. 
Lungs were excised, fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer 
(pH 7.2), containing 20 mM calcium chloride for 2 h, followed by a 1 h post-fixation in 
buffered 1% osmium tetroxide. The fixed left lung was then sectioned into a single 
transverse cut of the axial airway between lateral branches 1 and 2 and embedded in 
Embed 812 epoxy resin (14120 EMS). Sections of 100 nm thickness were stained with 
uranyl acetate and lead citrate and were viewed at 8200× magnification in a Tecnai 12 
transmission electron microscopy. Secretory cells were randomly selected and imaged, 
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and at least 19 images were used per mouse. Vv and Sv were obtained with randomly 
placed dot and line grids (line pairs, 64 tiles) on the cell profiles (142). To measure the 
relative electron lucency of mucin granules, a cycloid stereological grid with circles of 
30 pixels in diameter was randomly superimposed on the images. At least 5 circles that 
fell on nuclear heterochromatin and electron-lucent extracellular space were selected, 
and their grayscale value (0–255) was recorded. These values were used to set a linear 
scale for each image. Then at least 30 random circles that fell on granules were recorded 
using that scale. These data were recorded and the appropriate bin range and histogram 
distribution was calculated. 
 
2.5.7 Mucin transcript quantitative RT-PCR analysis  
Total RNA was extracted from whole lung (RNeasy mini kit; Qiagen) and 
reverse-transcribed (iSCRIPT, Bio-Rad). Quantitative PCR was carried out for each 
cDNA sample in triplicates with qPCR master mix (Quanta Biosciences) and 6-
carboxyfluorescein-labeled probes for Muc5b (Mm00466391_m1), Muc5ac 
(Mm01276725_g1) and -actin (Mm02619580_g1; all from Thermo Fisher Scientific) 
on a ViiA 7 RT PCR System (Applied Biosystems). Results were expressed as Ct 
(normalized for -actin) (143). 
 
2.5.8 Lung lavage  
This was performed by instilling and collecting 1 ml of PBS through a 
tracheostomy (20-gauge cannula). Total leukocyte count was determined using a 
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hemocytometer, and differential count by cytocentrifugation of 200 μl of lavage fluid at 
300 g for 5 min. Cytospins were stained by Wright-Giemsa for microscopic morphologic 
cell identification and counting. 
 
2.5.9 Mucociliary clearance  
Mucociliary clearance was measured as the elimination of fluorescent 
microspheres from the lungs over time. Mice were anesthetized with urethane (2 mg/g, 
i.p.) and tracheostomized with a blunt beveled 18 gauge Luer stub adapter (Becton, 
Dickinson). Using a microsprayer (Penn-Century), 25 l of PBS/0.1% Tween containing 
7.43x104 of 4.19 m fluorescent microspheres (Bangs Laboratories) were loaded at the 
lung carina through the tracheostomy. Lungs were harvested either immediately (time 0) 
or mice were mechanically ventilated with a flexiVent (Scireq, Canada) to guarantee 
uniform ventilation. Lungs were harvested after 30 min, homogenized with 1.5 g of 1.3 
mm chrome steel beads (BioSpec) and 1 ml of PBS/0.1% Tween using a Mini-Bead 
Beater (BioSpec) at 4800 rpm for 3 min. Fluorescent microspheres were then manually 
counted using a hemocytometer. 
 
2.5.10 Total bacterial 16S rDNA qPCR  
Lungs were harvested and bacterial genomic DNA was extracted and analyzed at 
Baylor College of Medicine by methods developed for the NIH-Human Microbiome 
Project (144, 145). Briefly, bacterial genomic DNA was extracted using a PowerSoil 
DNA Isolation Kit (MO BIO Laboratories, California) following the manufacturer’s 
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instructions. Extracted DNA concentrations were measured by Qubit (Life 
Technologies) for subsequent normalization of quantitative PCR results (qPCR). qPCR 
sample analysis was performed in a 7500 Fast Real-Time PCR System. The qPCR 
primers (1369F-1492R) target regions flanking V9 of the 16S rRNA gene (146). A 
standard curve was made using a serially diluted plasmid that contains nucleotides 1369 
to 1492 of an E. coli 16S rRNA gene, and concentrations of the samples were calculated 
from CT values using the equation generated from plotting the standard curve. All 
samples were run in triplicate, including the standard curve, a set of non-template 
controls (NTC), and inhibitor controls (known positives + unknown DNA).  
 
2.5.11 16S rRNA gene compositional analysis  
The 16S rDNA V4 region was amplified by PCR and sequenced in the MiSeq 
platform (Illumina) using the 2x250 bp paired-end protocol yielding pair-end reads that 
overlap almost completely. The primers used for amplification contain adapters for 
MiSeq sequencing and dual-index barcodes so that the PCR products may be pooled and 
sequenced directly (147), targeting at least 10,000 reads per sample. The read pairs are 
demultiplexed based on the unique molecular barcodes, and reads are merged using 
USEARCH v7.0.1001 (148) allowing zero mismatches and a minimum overlap of 50 
bases. Merged reads are trimmed at first base with Q5. In addition, a quality filter is 
applied to the resulting merged reads, and reads containing above 0.05 expected 
errors are discarded. 16S rRNA gene sequences were assigned into Operational 
Taxonomic Units (OTUs) or phylotypes at a similarity cutoff value of 97% using the 
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UPARSE algorithm. OTUs were then mapped to an optimized version of the SILVA 
Database (149, 150) containing only the 16S v4 region to determine taxonomies. 
Abundances were recovered by mapping the demultiplexed reads to the UPARSE OTUs.  
 
2.5.12 Lumenal occlusion in an allergic asthma model  
Airway mucus plugging was measured by modifications, as follows, of a method 
we have described previously (38). Lungs were fixed by immersion, to avoid 
displacement of lumenal mucus by inflation, in methanol-based Carnoy’s solution 
(methacarn), to minimize changes in mucus volume, for 48 h at 4°C. Lungs were then 
excised, and the right caudal lobe (Figure 6, B and figure S6, B), or every lobe (Figure 
S6, A), was embedded in paraffin. For Figure S6, A and Figure S6, B, a 5 m section 
was obtained every 500 m starting from the most caudal point of the lobe. For Figure 6, 
B, a 5 m section was obtained every 1 mm section of the right caudal lobe, yielding 4 
sections per lung. Slides were then deparaffinized, rehydrated, and stained with PAFS. 
Images were acquired using an upright microscope (Olympus BX 60) with a 20× NA 0.5 
lens objective. For quantification, the cross-sectional area of the lumenal mucus was 
traced (Figure 6, B), and the airway cross-sectional area was also traced to calculate the 
occlusion fraction (Figure S6, A and figure S6, B), using ImageJ (NIH). 
 
2.5.13 Lung mechanics  
Respiratory resistance was analyzed using a flexiVent system (Scireq). Mice 
were anaesthetized with urethane (3 mg/g by i.p. injection, a dose sufficient for 2 h of 
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sedation even though experiments last less than 30 min), and paralyzed with 
succinylcholine chloride (5 mg by i.p. injection followed by continuous i.p. infusion at 
20 μg/g∙min). Mice were tracheostomized with a blunt beveled 18-gauge Luer-Stub 
adapter and ventilated at 150 breaths/min, 10 μl/g, against 2-3 cm H2O positive end-
expiratory pressure. Respiratory resistance was assessed at baseline and in response to 
four incremental doses of methacholine (MCh) (1, 3, 10 and 30 mg/ml) administered by 
an in-line ultrasonic nebulizer (4-6 μm, Aerogen, Ireland). Total respiratory resistance 
was calculated by averaging eight values measured after each dose of MCh for each 
mouse. 
 
2.5.14 Lumenal occlusion and emphysema in the -ENaC-Tg model of cystic fibrosis  
Lungs were fixed with 10% NBF and the left lobes were cut in transverse 
sections starting at the level of the hilum and then every 2 mm from rostral to caudal, 
yielding 2-4 slices. All slices were embedded in paraffin, and a 5 m section was 
obtained from each slice. Sections were then stained with Alcian Blue-Periodic Acid 
Schiff (AB-PAS) (63). Whole lung section images were obtained in an Olympus 
BX61VS scanner with a BX81 stage and UPlanSApo 20× NA 0.75 objective lens; 
scanning conditions were kept constant among specimens. Lumenal occlusion was 
quantified as in Fig. 5, B from the first 2 sections of each mouse. Emphysema was 
measured using D2, the equivalent mean diameter, computed from measurement of 
airspace area, and weighted for variance and for skewness towards large spaces (151), 
from 10 high magnification non-continuous images (1134 × 1134 pixels), equidistant 
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from the center of the section and excluding airways, selected from the sections used in 
Figure 6, B. 
 
2.5.15 Statistics  
All statistical analyses were performed using GraphPad Prism 7.0 with P<0.05 
considered statistically significant. Exact P values and n values for each sample are 
included in each figure legend. Statistical analysis was performed using one-way 
ANOVA followed by Tukey’s post hoc test for multiple pair-wise comparisons, and 
Student’s t test or Mann-Whitney U test after determining normality of the data using 
D’Agostino-Pearson omnibus K2 test. A Kolmogorov-Smirnov test was used for Figure 
S5, D. Values that did not reach significance were not noted. After determining that the 
expression and secretory function of Munc18 proteins in floxed mice was equivalent to 
WT, the primary endpoint for studies of secretion, clearance and obstruction was of 
differences between airway deletant mice and their floxed littermates. 
 
2.5.16 Study approval  
All mice were kept in pathogen-free facilities and handled in accordance with the 
Institutional Animal Care and Use Committees of The University of Texas MD 
Anderson Cancer Center, The Texas A&M University Health Science Center Institute of 
Bioscience and Technology and The University of North Carolina. 
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CHAPTER III 
OTHER WORK 
 
During the course of my PhD, I have contributed to other projects that I will 
discuss briefly below. 
 
3.1 SNAP23 is selectively expressed in airway secretory cells and mediates baseline 
and stimulated mucin secretion 
 SNAP23 is one of the family of t-SNAREs that, as we discovered, is present in 
airway secretory cells and is responsible for both baseline and stimulated mucin 
secretion (Fig. 3.1). I made a technical contribution to all aspects of the paper (152). This 
was the first project that I contributed to, and since I was new in the laboratory, it helped 
me learn techniques that I then used for my main project on Munc18 (Chapter II). This 
went from the very basic, such as to learning how to handle mice and manage a 
genetically modified mouse colony, to advanced techniques such as how to analyze 
respiratory resistance upon a methacholine challenge and how to measure mucin 
secretion by image analysis.  
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Figure 3.1. SNAP23 is responsible for baseline and stimulated mucin secretion. (A) 
PAFS images show spontaneous mucin accumulation in the airways of SNAP23 
heterozygous mice and are quantified in the adjacent bar graph. (B) Stimulated secretion 
was examined by PAFS staining of airways of mice with mucous metaplasia (top row), 
then treated with an aerosol of ATP to induce acute mucin secretion (bottom row). 
Intracellular mucin content is quantified in the adjacent bar graphs. Reprinted from 
(152). 
 
 
 
3.2 Aerosolized TLR agonists suppress acute Sendai virus lung infection and 
chronic asthma-like lung disease in mice 
 One of our laboratory side projects consists of stimulating innate immunity 
within the lungs to reduce the severity of a respiratory viral infection in the short term 
and the resulting severity of virus-induced asthma in the long term. My part in this 
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project started with the observation that lungs of mice infected with Sendai virus showed 
multiple yellow nodules on their surface 49 days after infection (long term phenotype). 
Histopathologic staining of the nodules showed alveolar accumulation of characteristic 
macrophages heavily laden with lipids leading to the hypothesis that mucus plugs were 
causing this accumulation, which is characteristic of chronic airway obstruction. I 
evaluated the post-infected lungs and indeed saw that mucus plugs were present, and that 
stimulating innate immunity before the viral infection reduced the presence of plugs 
(Fig. 3.2). The plugs were then probed with mucin antibodies which demonstrated that 
both Muc5ac and Muc5b were present. In addition to mucus plugging, respiratory viral 
infection caused mucous metaplasia in the long term, providing an explanation for the 
presence of plugs. The project resulted in a manuscript that is nearly ready for 
submission to Science Translational Medicine.  
 
 
Figure 3.2. Lungs infected with Sendai virus display airway mucus occlusion. Cross-
section of an infected lung stained with PAFS showing mucous metaplasia and airway 
mucous occlusion. Cross-sectional area of lumenal mucus was quantified and is shown 
in the adjacent bar graph. 
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3.3 Inflammation-induced upregulation of P2X4 expression augments mucin 
secretion in airway epithelia 
 It is well established that ATP induces mucin secretion in the airway epithelium 
via metabotropic P2Y2 purinoreceptors. However, the P2X family of ionotropic ATP 
receptors is less studied and their specific cell type expression has not been reported. Our 
collaborator, Manfred Frick from Ulm University, wanted to address this gap in 
knowledge and contacted us based on our ability to isolate airway secretory cells by 
fluorescence activated cell sorting (FACS). This technique, which is mentioned here for 
the first time in this document, has been developed over time in our laboratory. A key 
breakthrough was when I deciphered by immunofluorescence microscopy that the Cre 
we were using, CCSPiCre, with the Cre recombinase improved for mammalian codon 
usage and knocked into the CCSP locus that is specific for secretory cells (116), was not 
in fact specifically expressed in airway secretory cells, but was active throughout the 
whole airway epithelium. This now makes sense since new studies have been published 
showing that ciliated cells develop from secretory club cells (117), so a CCSP-driven 
Cre recombinase must be expressed post-developmentally in order to only target 
secretory cells. Going back to the P2X4 project, we needed to sort specifically for airway 
secretory cells and not ciliated cells, so we used an inducible Cre, one conjugated to a 
mutated estrogen receptor (CCSPCre-ER). This allowed for recombination in the mature 
adulthood epithelium only within airway secretory cells. For our cell sorting, we cross a 
double fluorescent reporter mouse (mT/mG) (153) with the mouse carrying the modified 
Cre necessary for our study. 
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 The utilization of this method along with other techniques allowed Dr. Frick to 
demonstrate that P2X4 receptors are expressed in the plasma membrane and in vesicular 
structures of airway secretory cells specifically distinct from mucin granules, and even 
upregulated under conditions of chronic inflammation that include mucous metaplasia 
(Fig. 3.3). P2X4 receptors are ligand-gated calcium channels that are activated by 
extracellular ATP and allow for the increase of intracellular calcium concentrations. 
Activation of the receptors by extracellular ATP augments stimulated mucin secretion, 
whereas mucin secretion is dampened by inhibition of P2X4 receptors. This work is 
under review as a resubmission to the American Journal of Physiology.  
 
 
Figure 3.3. P2X4 is expressed in vesicular structures in goblet cell. 
Immunofluorescence staining of human primary tracheal epithelial cells expressing wild-
type P2X4-EGFP (green), and stained for MUC5AC (red). Nuclei is shown in blue. 
Reprinted from (154). 
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3.4 Ascaris larval infection and lung invasion induces mucin production and airway 
mucus occlusion 
   Ascaris lumbricoides is the most common helminth infection globally and a 
cause of life-long morbidity. Our collaborator, Jill Weatherhead, from Baylor College of 
Medicine, was evaluating the immunological and histopathological changes during 
Ascaris infection in a mouse model. We established a collaboration to investigate the 
mucus response during and after the infection.  
 Our first question was to see if there was a mucus response and to characterize its 
extent. We analyzed lungs at day 8 of infection, since that is when the maximal number 
of worms are traversing the lungs. Mice are infected with eggs at day 0 by oral gavage, 
larvae hatch and penetrate the small intestine, then enter the liver through the portal 
system, enter the lungs via the systemic circulation, exit the lungs through the trachea, 
get swallowed, infect the intestinal lumen and are eliminated around day 14. By PAFS 
staining, we found that Ascaris infection induced mucous metaplasia and airway mucus 
occlusion, and to a similar extent as in our IL-13 allergic model (Fig. 3.4). To determine 
if Muc5b or Muc5ac were preferentially upregulated in this model, we probed the mucus 
plugs with antibodies against the two mucins. We found that both mucins were present 
and were being secreted into the airway lumen (Fig. 3.4).  
 Next, we wanted to see if studying one section of the lung, for example, the left 
lobe, would be a fair representation of what is happening throughout the whole lung, so 
other portions of the lungs could be used for other purposes in the future. In other words, 
we were wondering if worms preferentially migrated through the anterior or posterior 
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region, the right or left side, or the rostral or caudal region. We therefore examined the 
infected lungs rigorously through several transverse sections via PAFS staining and 
concluded that there was no differential mucin expression or secretion in any particular 
lung anatomic area other than the lung periphery, where there is a lack of mucin-
producing airways. This work ended in an accepted publication in Infection and 
Immunity. 
 
 
Figure 3.4. Airway mucus occlusion in lungs infected with Ascaris lumbricoides. 
Left: Cross-sectional area of lumenal mucus was quantified in lungs infected with 
Ascaris or stimulated with IL-13. Right: Immunofluorescence staining of a cross section 
of an airway mucus plug showing Muc5b in green and Muc5ac in red. Nuclei is shown 
in blue. 
 
 
 
 This project is ongoing and we are now investigating whether the trapping of 
helminths during migration through the lungs might be impaired by Munc18b deletion, 
building upon discoveries made in my main project (Chapter II). 
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3.5 MyD88 controls airway epithelial Muc5ac expression during TLR activation 
from agricultural organic dust exposure 
 Our collaborator, John Dickinson from the University of Nebraska, who has 
recently become an assistant professor, investigates how agricultural organic dust extract 
(ODE) induces airway inflammation and mucous metaplasia. His key endpoint was to 
quantify the mucus response to ODE in a MyD88 mutant mouse, since ODE is known to 
activate inflammation through TLR activation of MyD88. We helped him developed the 
techniques he needed to address his questions, such as immunofluorescence microscopy 
using mucin antibodies developed by our laboratory, and most importantly, Western 
blots for mucins using whole lung tissue which were developed in our laboratory too. Of 
note, prior work with mucin Western blots had generally started with extracellular 
mucus, such as that obtained from lung lavage fluid or cell culture supernatant. Mucins 
are notoriously difficult to study, since they are big proteins, heavily glycosylated and 
often entangled. To develop a reliable technique, I travelled to the University of North 
Carolina-Chapel Hill in 2017 to work with Mehmet Kesimer, a biophysicist. Building 
upon existing methods used in our laboratory (118), the key component to add to the 
sample is DNase to improved our electrophoretic resolution (see Methods section of 
Chapter II). With these techniques in hand, Dr. Dickinson found that deleting MyD88 
paradoxically increases Muc5ac production after ODE exposure compared to WT mice 
(Fig. 3.5). He concluded that ODE is signaling mucous metaplasia through non-TLR 
pathways that could activate transcription factors that upregulate Muc5ac gene 
expression such as SPDEF, and that MyD88 inhibits this pathway. Thus, MyD88 
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promotes neutrophilic inflammation in response to ODE, but suppresses mucous 
metaplasia. This work is under review as a resubmission to the American Journal of 
Physiology.  
 
 
Figure 3.5. MyD88-deficient mice have increased mucin levels with ODE-mediated 
inflammation. Representative mucin Western blots from whole lung homogenates for 
Muc5ac (left) and Muc5b (right) with corresponding quantification of band 
densitometry. Reprinted from (155). 
 
 
 
3.6 Airway mucin secretion 
 I wrote a review article with Dr. Dickey and other members of the laboratory that 
summarizes what we have learned about airway mucin secretion as a result of my studies 
and work by others. This article is in press in Annals of the American Thoracic Society, 
and some of the conclusions and future directions discussed below in Chapter IV are 
elaborated in this article.  
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CHAPTER IV 
DISCUSSION AND CONCLUSIONS 1 
 
4.1 Discussion 
 After a comprehensive analysis, we have found that baseline and stimulated 
mucin secretion are predominantly mediated by different Munc18 proteins, with 
Munc18a having the major role in baseline secretion and Munc18b having the major role 
in stimulated secretion. Importantly, the existence of two different Munc18 proteins 
regulating different rates of mucin secretion allows the possibility to target the 
pathologic consequences of stimulated mucin secretion without impairing toxicant 
clearance. 
 Previously, when talking about mucin secretion, two mechanisms were plausible. 
One was that a single secretory machine was responsible for both rates of mucin 
secretion, baseline and stimulated, wherein a rise in intracellular calcium concentration 
would increase the rate of the one machine. The other possibility was the presence of 
two secretory machines. The project described in Chapter II unambiguously 
demonstrates the presence of two machines. 
                                                 
1 Part of this chapter is reprinted with permission of the American Thoracic Society. 
Copyright © 2018 American Thoracic Society.  
Jaramillo AM, Azzegagh Z, Tuvim MJ, Dickey BF/Airway Mucin Secretion by  
Annals of the American Thoracic Society is an official journal of the American Thoracic 
Society. 
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 Since Munc18 proteins transport Syntaxins to the plasma membrane and hold 
them in a closed conformation to prevent nonspecific binding with other SNARE 
proteins, their interaction is specific. For example, Munc18a will bind Syntaxin-1 but 
Munc18b will not. This strongly suggests that different Syntaxins could mediate baseline 
and stimulated mucin secretion too. A recent study also found that Munc18 proteins bind 
to VAMPs before the complete SNARE complex is formed, docking the vesicle close to 
the plasma membrane and bringing the SNARE proteins together. This would then 
suggest that different VAMPs could mediate the different rates of mucin secretion. There 
is a study that shows that VAMP8 has a role in stimulated mucin secretion, but its role in 
baseline was not well defined (104). With the knowledge of the two machines that my 
project generated, new preliminary data in our laboratory using mutant mice suggests the 
presence of a different VAMP isoform in baseline secretion, VAMP3. This isoform is 
expressed in airway epithelial cells and has been shown to have a role in other secretory 
pathways, such as secretion of Weibel-Palade Bodies in endothelial cells and granule 
release in platelets (156, 157).  
 A key open question is whether the baseline and stimulated mucin secretory 
machines interact selectively with Muc5ac, Muc5b, and other secretory products. Four 
possible models of interaction between the plasma membrane machines and secretory 
vesicles are illustrated in Figure 4.1. The first two of these are considered highly 
unlikely because there would be no apparent value to the existence of separate plasma 
membrane machines in these models (Fig. 4.1 A and B). In the third model (Fig. 4.1 C), 
the baseline exocytic machine is hypothesized to interact selectively with smaller 
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granules early in their maturation after leaving the trans-Golgi network. As the granules 
further mature and enlarge through lateral fusion, the baseline VAMP and Syt proteins 
would be removed and replaced by the stimulated machine components VAMP8 and 
Syt2. This model is reminiscent of the Rab conversion model that directs traffic from 
early to late endosomes (135). The possible utility of this model could be that baseline 
secretion of small granules would minimize the chance of airway occlusion during 
healthy conditions with its adverse consequences for airflow (38), while the stimulated 
secretion of large granules would maximize the chance of airway occlusion to trap 
migrating helminths during infection. In the fourth model (Fig. 4.1 D), the baseline 
exocytic machine is hypothesized to interact selectively with granules containing 
Muc5b, whereas the stimulated machine would interact selectively with granules 
containing Muc5ac. The possible utility of this model could be the selective release of 
Muc5b for baseline mucociliary clearance, consistent with its demonstrated functional 
role (26), and the selective explosive release of Muc5ac to trap helminths, again 
consistent with it demonstrated function (36). Muc5ac and Muc5b have been shown to 
occupy distinct domains in lumenal mucus (10, 82, 139, 158). With the help of 
deconvolution microscopy, preliminary data from our laboratory also show that they 
may be packaged in distinct granules, favoring the fourth model.  
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Figure 4.1. Models illustrating the possible interactions of the two regulated 
exocytic machines of airway secretory cells with mucin granules. In each model, B 
designates the baseline exocytic machine and S designates the stimulated machine. 
Green dots within the secretory granules designate Muc5ac, and blue dots designate 
Muc5b. Munc18 has been shortened to M18 to avoid clutter, and “?” is used to designate 
an unknown isoform of VAMP or Syt (synaptotagmin) proteins.  
 
 
 
4.2 Conclusions 
 In summary, my principal work was to build upon prior studies in the Dickey 
laboratory to test whether or not a single core exocytic machine mediates all airway 
epithelial mucin secretion. My finding that two different Munc18 proteins mediate 
baseline and stimulated mucin secretion firmly establishes the presence of two machines. 
This finding is now serving as an anchor for the laboratory to identify additional 
components of the machines, analyze their regulation, and dissect the trafficking of 
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different cargo proteins. In side projects, I used my increasing expertise in mucin 
biochemistry and cell biology to contribute to work being done in other laboratories.  
 
4.3 Future work 
4.3.1 Identification of Syntaxins in baseline and stimulated mucin secretion 
 The remaining t-SNARE proteins in mucin secretion that belong to the Syntaxin 
family remain unknown. Identifying these proteins would be of importance as it would 
complete the molecular dissection of the core exocytic machinery responsible for mucin 
secretion. There are several hints that our previous research and research by others have 
provided. The first comes from the fact that there is a close and specific interaction 
between SM proteins and Syntaxins. This implies that, since we have two different 
Munc18s, one for baseline secretion and one for stimulated secretion, then there is a high 
probability that there are also two different Syntaxins present. The close interaction 
between these two proteins also provides us with clues as to which isoforms might be 
present, as some SM proteins have greater affinity for certain Syntaxins than others. Out 
of the 19 members of the Syntaxin family, we can already narrow it down to a handful of 
isoforms. For example, previous studies by us and others have shown that Munc18a 
interacts with Syntaxins 1, 2 and 3, whereas Munc18b interacts with Syntaxins 2, 3 and 
11 (65, 159-161). 
 Syntaxin 11 was a particularly attractive candidate because it partners with 
Munc18b in cytolytic T cells and natural killer cells, as revealed by mutational analysis 
in familial hemophagocytic lymphohistiocytosis and confirmatory cellular studies (160, 
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162, 163). However, we have already obtained a conditional deletant mouse for Syntaxin 
11 and have ruled out a role in baseline or stimulated mucin secretion. Syntaxin 3 is also 
an attractive candidate because it partners with Munc18b in apical secretion in other 
polarized epithelial systems (122, 164-166). We have also obtained a conditional 
deletant mouse for Syntaxin 3 but have not been able to study it since a complete 
deletion of the gene in the airway epithelium impairs mouse viability; and contrary to 
our Munc18b and SNAP23 mutant mice, deletion of one allele of the Syntaxin 3 gene in 
the airway epithelium does not provide a phenotype in either baseline or stimulated 
mucin secretion. Because of all these problems, the approach we are now taking is to 
induce recombination during adulthood using the tamoxifen-inducible CCSP-CreER 
construct to delete Syntaxin 3 gene from the airway epithelium. The remaining Syntaxin 
3 protein left in the cell will degrade over time until levels become too low for the cell to 
be viable. Our plan is to study the role of Syntaxin 3 in mucin secretion just before cell 
death, in other words, when there is more than a 50% reduction in protein levels so as to 
detect a secretory phenotype but just enough for the cell to be viable. The temporal 
degradation of the protein would be established by Western blots of sorted secretory 
cells. 
 Assuming that Syntaxin 3 partners with Munc18b to function in stimulated 
mucin secretion, our leading candidate to study for baseline mucin secretion would be 
Syntaxin 1. Syntaxin 1 is a well studied protein and is a partner of Munc18a in 
neurotransmitter exocytosis. The difficulty with testing this candidate is that it is 
composed of two isoforms, Syntaxin 1a and 1b, and -1a complements -1b upon deletion. 
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Nevertheless, conditional deletants of both isoforms exist and are readily available. If 
Syntaxin 1 is not found to mediate baseline mucin secretion, then Syntaxin 2 is another 
candidate, and knockout mice are available (167). 
 
4.3.2 Mucin granule identity  
 VAMP proteins belong to the v-SNARE group and are located in the granule 
membrane. The VAMP protein responsible for stimulated mucin secretion has been 
already identified by another group as being VAMP8 (104). Preliminary data from our 
laboratory using VAMP3 knockout mice indicates that VAMP3 is the one functioning in 
baseline mucin secretion. Based on our four models proposed in Figure 4.1, we also have 
some preliminary data that supports model 4, suggesting that Muc5b and Muc5ac are 
packaged in distinct granules. This leaves us the question of whether VAMP proteins are 
segregated into different granules too, having VAMP3 on Muc5b granules and VAMP8 
on Muc5ac granules. Answers to this question should be achieved with 
immunofluorescence and deconvolution microscopy. 
 Cells may not also be exclusively selecting cargo to be sorted in different 
granules. The different packaging we are seeing in our preliminary results may be 
restricted to certain types of cells, or at least to different temporal stages of the cell after 
induction of mucous metaplasia by inflammatory cytokines. Moreover, upon deletion of 
important trafficking machinery such as VAMPs, cargo segregation may not be 
preserved anymore, prompting Muc5b and Muc5ac to be trafficked in the same granules. 
This problem then leads us to the next question, which is what happens to the cargo, i.e. 
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mucins, when VAMPs are deleted? Cargo sorting at the trans-Golgi network is still not 
well characterized for big proteins (jvb). VAMP proteins may exit the Golgi with the 
mucin granule but they may also be incorporated at a later stage. Thus, if VAMPs are 
required for cargo sorting, one problem arising upon deletion of VAMPs could be 
aggregation of mucins at the Golgi. What we also don’t know is what other cargo is 
being packaged into mucin granules. Previous data from our lab suggests that CCSP 
partially colocalizes with mucins, but the identity of the mucin and the degree of the 
colocalization remains to be studied. What would happen to other cargo upon deletion of 
VAMPs? Is the secretory machinery important for granule biogenesis? These are several 
important questions that remain to be addressed and this will mainly be the focus of the 
laboratory for the next years. 
 
4.3.3 Development of Munc18b as a therapeutic target 
The generation of a Munc18b-targeted therapy would be of great interest as 
mucus dysfunction contributes to the symptoms and pathophysiology of many common 
diseases. There are several ways to target this protein. First, direct deletion of the gene in 
airway epithelium with the use of CRISPR/Cas9 (Clustered Regularly interspaced Short 
Palindromic Repeats/CRISPR-associated protein 9) or targeting of the transcripts using 
siRNAs. Gene silencing by siRNA is already in the clinic, and is being pursued in 
airway epithelium by several companies. The Dickey laboratory is collaborating with 
Arrowhead Pharmaceuticals to target Munc18b using their siRNA technology. 
CRISPR/Cas9 gene therapy in airway epithelium is being actively pursued for correction 
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of mutations in cystic fibrosis, and if this technology is developed successfully, it could 
be used to target Munc18b.  
At the protein level, Munc18b can be targeted with the use of stapled peptides. 
These stapled peptides are designed to have a 3D configuration that allows them to bind 
a protein of interest while retaining conformation and resisting degradation. Specifically 
for Munc18b, a good targeting region would be its interacting pocket with Syntaxin, or 
the interacting region with VAMP. This would impede Munc18b-SNARE complex 
formation inhibiting stimulated mucin secretion. One caveat with targeting Munc18b is 
that it may disrupt Syntaxin localization in the plasma membrane. As we already know 
our secretory cells are not viable without Syntaxin 3, if Syntaxin 3 is the isoform 
responsible for stimulated mucin secretion, then it would be better to target other 
functions of Munc18b and not its Syntaxin interaction region. This strategy is being 
pursued by the Dickey laboratory in collaboration with Dr. Phil Jones of the MD 
Anderson Institute for Applied Cancer Science and Dr. Axel Brunger, a structural 
biologist at Stanford University.  
 
4.3.4 Summary 
Further work on molecular mechanisms of baseline and stimulated airway mucin 
secretion is likely to lead to new cell biological insights, and possibly to further 
understanding of disease mechanisms and avenues for therapeutic intervention. 
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